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ABSTRACT 
Cervical spondylotic myelopathy (CSM) is the most common cause of spinal cord dysfunction in 
older adults and results in motor and sensory dysfunction. CSM can present abruptly with severe 
symptoms of neurological impairment or insidiously with a slow stepwise deterioration. There is 
no current imaging modality or biomarker that can help predict which patient will successfully 
respond to conservative versus surgical treatment. Previous research suggests that surgical 
intervention triggers functional alterations in the CSM patient sensorimotor cortex. The goal of 
this thesis was to follow a group of CSM patients longitudinally to assess how brain function, 
metabolism, and structure correlate to clinical outcomes in the context of recovering neurological 
function following surgery.  
 
Chapter 1 of this thesis provides a detailed literature review of the current controversies in 
treating CSM, specifically between mild and moderate severities of CSM. Novel imaging 
techniques that can elucidate cortical adaptations in CSM patients are discussed. In chapter 2, the 
cortical metabolite profile was characterized in a group of CSM patients using proton magnetic 
resonance spectroscopy (MRS). A lower N-Acetylaspartate (NAA) to creatine (Cr) ratio was 
found in the CSM patients with decreased neurological function compared to controls, indicative 
of neuronal death or mitochondrial dysfunction. In chapter 3, the metabolite changes in the 
primary motor cortex of CSM patients are shown to recover following successful surgical 
intervention. The structural integrity of the white matter adjacent to the primary motor and 
sensory cortices was also assessed using diffusion tensor imaging (DTI). The DTI results 
indicated maintenance of white matter and axonal integrity, while a decrease in NAA/Cr 
following surgery suggested neuronal mitochondrial impairment. Our findings of a clear 
neurological improvement in CSM patients following surgery support the hypothesis that 
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neurological recovery may require the recruitment of surrounding cortex, given that focal 
recovery in the motor cortex may be metabolically unattainable. In chapter 4, functional MRI is 
used to study the cortical adaptation and reorganization that occurs in mild and moderate CSM 
severities, prior to and following decompressive surgery. The goal was to determine whether 
there are critical factors (metabolite and/or functional) that can classify patients along a spectrum 
of injury severity, and predict successful surgical outcome. This study found distinct metabolic 
and functional profiles in the motor cortex that discriminate between mild and moderate CSM 
patients prior to surgery. We propose mitochondrial dysfunction, indicated by low levels of 
NAA/Cr, as the primary trigger for cortical reorganization and recruitment leading to functional 
improvement. Collectively, this thesis utilizes novel imaging methods to explore how the cortex 
adapts and compensates for neurological deficits, distal to the site of injury, and attempts to 
identify new imaging biomarkers to characterize  the severity of CSM and predict functional 
recovery.  
Keywords: 
cervical spondylotic myelopathy; spinal cord compression, neuroimaging, functional MRI, 
magnetic resonance spectroscopy, diffusion tensor imaging, N-Acetylaspartate, white matter, 
brain reorganization, disease severity 
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CHAPTER 1: 
INTRODUCTION AND GOAL OF THESIS 
2 
1. 1 Cervical Spondylotic Myelopathy 
Cervical spondylosis is used to describe the degenerative changes of the spine that become 
increasingly more prevalent with aging. In its most severe form, spondylosis can lead to 
compression of the spinal cord referred to as cervical spondylotic myelopathy (CSM).1-3 CSM is 
the most common form of spinal cord dysfunction in people over the age of 55.2,3 Male patients 
are preferentially affected at a ratio of 2.7:1 and spinal cord compression can occur at multiple 
levels with C5-C6 being the most common.2,4-5 A majority of the older population will show 
signs of pathological or radiographic evidence of cervical degeneration, and the progression to 
CSM with symptoms of neurological impairment becomes more prevalent with increasing age.2,6 
The CSM population is heterogeneous with symptoms ranging from mild dysfunction, such as 
numbness or problems with dexterity, to severe, such as quadraparesis and incontinence.1-4 The 
diagnosis of CSM can be difficult as the onset of symptoms is usually insidious with long periods 
of disability and short episodes of worsening.2 Each year thousands of Canadians with worsening 
spinal cord compression, debilitating symptoms and failure to respond to alternative treatments 
will require surgical intervention. Current assessments include patient history, physical 
examination, x-ray, and magnetic resonance imaging (MRI). Nonetheless, clinical improvement 
is difficult to predict. There is a need for improved pre-operative screening to predict the outcome 
of decompressive surgery in this debilitating disease.  
 
1.1.1 Pathophysiology and Pathology of CSM 
As part of normal aging, degenerative changes occur in various components of the spine such as 
the vertebral body, intervertebral disc, supporting ligaments and facet joints, eventually leading 
to narrowing of the spinal canal at one or more levels.2,5-6 CSM results from this degeneration 
and the primary mechanism of injury is secondary to compression of the spinal cord (Figure 
3 
1.1).2 The degenerative cascade typically begins with the deterioration of the intervertebral disc. 
The disc collapses and the annulus bulges posteriorly causing narrowing of the spinal canal. 
These changes can lead to osteophyte formation and increase the stress on the facets.2,6 Decreased 
disc height also causes the spinal column to shorten, leading to alignment changes.2,5 The 
ligamentum flavum thickens and buckles into the spinal canal. Ossification of the posterior 
longitudinal ligament, most commonly seen in Asian populations, can also lead to CSM by direct 
compression of the spinal cord.7 In conjunction, hypermobility and abnormal spine biomechanics 
cause hypertrophy and ossification of the facets, posterior longitudinal ligament and ligamentum 
flavum.2,5-6 Congenital narrowing or acquired subluxation, uncovertebral joint thickening and 
osteoarthritis can also play a part in narrowing of the spinal canal.2 As the degenerative cascade 
continues, the affected vertebrae become stiffer, and initiate hypermobility at adjacent vertebrae.2  
 
 
Figure 1.1: A sagittal (left) and axial (right) T2-weighted image of the cervical 
spine. The red arrows point to the cord compression at the C4-C5 level due to 
intervertebral disc bulging. 
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Spondylotic changes happen concurrently with static factors responsible for stenosis, and 
dynamic factors causing repetitive injury to the cord and ischemia. Static factors include a 
congenitally narrow canal, osteophyte formation, hypertrophy of the ligamentum flavum, 
ossification of the posterior longitudinal ligament and subluxation.2,3 Static factors cause 
structural degenerative changes that decrease the size of the spinal canal from its normal cervical 
canal diameter of 17-18 mm in Caucasians from the C3-C7 levels (with some variation between 
genders).8 Dynamic factors refer to abnormal repetitive movement of the cervical spine during 
flexion and extension causing nerve root and spinal cord irritation and compression. During 
flexion, the spinal cord stretches and can be compressed against anterior osteophytic spurs and 
intervertebral discs.2,7,9 Hyperextension may lead to spinal cord “pinching” between the posterior 
margin of the vertebral body anteriorly and the hypertrophied ligamentum flavum posteriorly.2,7,9 
The third factor, ischemia, occurs when the blood vessels that supply the spinal cord and nerve 
roots are compressed by degenerative structures.9 The ischemia and the decreased blood flow 
may initiate apoptosis, which is suggested to be the primary cellular process underlying the 
disappearance of oligodendrocytes in CSM.10-11 Oligodendrocytes aid in neurological 
development, repair of axonal injury and in the formation of myelin.11  
 
Pathological findings due to mechanical compression and restricted microvasculature likely result 
in gray and white matter degeneration, cystic cavitation, gliosis, posterolateral white matter 
demyelination, sparing of anterior columns, and atrophy of the anterior horns.8,12  
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1.1.2 Clinical Presentation 
The onset of symptoms is usually insidious with long periods of disability and short episodes of 
worsening, however symptoms can develop acutely or transiently.2 Pain is not always associated 
with the progressive loss of function and patients learn to adapt, attributing the slow progression 
to natural aging.3 In the early stages of CSM, common presentation includes neck stiffness, 
changes in muscle tone, superficial sensory loss, deteriorations in gait, balance and manual 
dexterity.3,7 Symptoms can progress to quadraparesis, incontinence and loss of urethral sphincter 
control.3,7 Patients who do progress, experience a large functional decline leading to a reduced 
quality of life.  
 
1.1.3 Natural History  
The natural history of CSM is unpredictable.13-16 Clarke and Robinson observed 120 CSM 
patients without treatment and found that 75% worsened in a stepwise fashion, 20% slowly 
worsened and 5% experienced rapid onset of symptoms without further progression.13 Epstein et 
al. found that in a series of 1355 patients, 36% reported improvement and 64% either remained 
stable or deteriorated in function.14 There are few predictors to determine which patients will 
experience spontaneous improvement and which will have progressive deterioration over time.  
 
1.1.4 Clinical Measurements 
Validated instruments for assessing disability resulting from spinal cord compression include the 
American Spinal Injury Association Impairment Classification (ASIA) Scale (Figure 1.2) and the 
modified Japanese Orthopaedic Association Score for CSM (mJOA).17 For the ASIA scale, the 
maximum motor score is 100 (50 for upper limb and 50 for lower limb) and the maximum 
sensory score is 112 for light touch and 112 for pin prick (Figure 1.2).  
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Figure 1.2: American Spinal Injury Association (ASIA) clinical assessment form. 
Source: http://asiaspinalinjury.org/elearning/ISNCSCI.php (accessed September 
2014, available for free download) 
 
The mJOA scale ranges from 3 to 18 points (with 18 representing the maximum score) and 
identifies upper and lower motor, upper sensory and sphincter function.18 To better understand 
this population, studies separate the CSM group into mild, moderate and severe based on the 
initial mJOA score.19 Mild CSM is defined as having a mJOA score of >12, moderate CSM 
patients present with a mJOA score between 9 and 12, and severe CSM cases have a mJOA<9.19 
Patient derived outcome tools commonly used for self-perceived measures of improvement 
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include the 36-item Short-Form Health Survey (SF-36)20 and Neck Disability Index (NDI).21 The 
SF-36 measures general health and is divided into two components: Physical component 
summary and Mental component summary. The NDI score has a total of 10 questions that range 
from 0 to 100 (with 100 representing the maximum score).  
 
1.1.5 Imaging (Diagnostic Evaluations) 
Cervical radiographs (plain x-rays) are often used to examine the narrowing of the disc space, 
presence and size of osteophyte formations, global sagittal alignment and focal translation or 
kyphosis.3,22 Computed tomography (CT) is also used to assess bony anatomy and ossification of 
the posterior longitudinal ligament. However, x-rays and CT scans provide limited information 
regarding the condition of the spinal cord. Currently, the most useful diagnostic tool remains 
MRI of the cervical spine, which shows the size and shape of the spinal cord in the sagittal, axial,  
and coronal planes. Signal changes, such as T2-hyperintensity or T1-hypointensity, within the 
cord can reflect atrophy of the cord or rule out other differential diagnoses.3 T2-hyperintensity at 
the level of the compression has been shown to correlate with symptom severity and represent 
oedema and inflammation.23-24 T1-hypointensity in images has been shown to correlate with 
worse prognosis and represent ischemia, myelomalacia or gliosis.23,25 The accuracy of T2 and/or 
T1-weighted signal changes as predictors of recovery of function are highly debated.23-25  
 
1.1.6 Conservative Treatment, Surgical Intervention and Predicting Outcome 
Conservative treatment is aimed at controlling pain and protecting the spinal cord from additional 
injury when there is radiographic evidence of spinal canal narrowing but limited signs or 
symptoms.2 This may include cervical immobilization with a soft collar, medications, avoidance 
of certain activities, acupuncture, physical and massage therapy. In a cohort of 45 patients, 82% 
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and 56% of CSM patients who undertook conservative treatment did not experience neurological 
deterioration at 5 and 10 years, respectively.26 Surgical decompression is reserved for patients 
with moderate or severe CSM exhibited by neurologic deficits during a clinical exam, severity of 
symptoms, rate of progression, and findings on x-ray and MRI.2 The goal of surgery is to 
decompress the spinal cord, preserve the alignment of the vertebra and prevent any further 
neurologic injury. However, surgical outcomes are unpredictable. Some studies report a 60% 
improvement while others suggest that the success rate of surgery is more variable with a third 
improving, 40% showing no change and 25% worsening.27-28 In addition, the complication rate 
has an average of 18.7%, with the most common complication being postoperative dysphagia.29 
Several factors have been suggested as predictors of surgical outcome such as: age, duration of 
symptoms, severity of myelopathy, mJOA score, cross-sectional area of spinal cord and high-
signal intensity changes on T2-weighted MRI.29-33  
 
1.1.7 Cortical Changes due to CSM 
The pathologic changes occurring in the spinal cord due to CSM have been studied extensively, 
but remain relatively unexplored in the cortex. In CSM, the spinal cord is compressed and the 
corticospinal tract is compromised. The pathways mediating the efferent and afferent flow of 
communication between the brain and spinal cord are disrupted and alterations within neural 
circuits may occur.  
  
When an injury to the spinal cord is sustained, a process called Wallerian degeneration occurs 
where axons distal to the site of injury undergo progressive retrograde deterioration.34 Wallerian 
degeneration occurs at the local injury site, however, whether there are significant changes that 
occur upstream in the cortical neurons is debated.35-37 Some animal studies report the majority of 
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neurons in the cortex are unaffected following a disrupted corticospinal tract and continue to 
remain receptive to incoming signals.36 In contrast, primate studies show apoptosis of 
corticospinal neurons in the motor cortex, and decreased synaptic spine density.35,37 Similarly, 
human studies following SCI demonstrated cortical atrophy in the somatosensory areas which 
related to the degree of sensory impairment.38 
 
Although little is known about the pathological changes in CSM, there is evidence that the 
maintenance of residual motor function and the recovery process involves reorganization of the 
cortex and the spared spinal motor neuron pools.39-40 The adaptive process may occur by the 
modification of pre-existing connections (synaptic plasticity) or the development of new circuits 
through sprouting of axons and dendrites.40 Reorganization of the cerebral cortex due to CSM 
and SCI will be discussed in further detail in the next sections.  
 
1.1.8 Limitations and the Solution 
With arthritis of the spine increasing in both prevalence and severity in our aging population, a 
precise and accurate tool is required to tailor the treatment of CSM and to ensure appropriate and 
efficient use of medical resources and technology. CSM is a unique model of reversible SCI 
providing an opportunity to examine mechanisms involved in injury, recovery, and possibly 
neuronal plasticity. Even though these factors are currently used to predict the extent of recovery 
following surgery, the existing evidence lacks the scientific rigor to present consistent and 
confident conclusions. Results from this heterogeneous group presenting with mild and moderate 
symptoms are variable using the current evaluation and follow-up criteria. For patients with early, 
mild symptoms of CSM, the timing of intervention is particularly controversial as select patients 
can stabilize clinically without operative intervention.  
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Management of mild CSM patients remains controversial. Kadanka et al. compared conservative 
and surgical treatment in mild-to-moderate CSM patients and showed no significant differences 
at 10 years with respect to mJOA score, score of daily activities, subjective assessment by 
patients and ability to walk 10-m track.41 Oshima et al. reported that 82% and 56% of mild CSM 
patients who undertook conservative treatment did not experience neurological deterioration at 5 
and 10 years, respectively.26 A recent study, however, reported that surgery resulted in improved 
functional, disability-related, and quality-of-life outcomes at 1 year in symptomatic CSM, even 
when the disease is mild.29 These results suggest that early surgical intervention may be 
preferable in cases of early, mild CSM.  
 
Although MRI remains the best imaging modality to visualize the spinal cord and the impact of 
spondylotic changes, the accuracy of T2 and/or T1-weighted signal changes as a predictor of the 
recovery of function following surgery are highly debated.24-25,32 Advanced MRI techniques, 
however, can be used to study the biochemistry, microstructure, and functional reorganization of 
the brain using techniques such as magnetic resonance spectroscopy (MRS), diffusion tensor 
imaging (DTI), and functional MRI (fMRI). Our group has shown cortical changes, distal to the 
site of injury in the spinal cord.42 Duggal et al. illustrated that reversible spinal cord compression 
(SCC) leads to an increased activated area within the primary motor cortex in comparison to 
controls.42 Surgical decompression resulted in cortical reorganization that was accompanied by a 
significant return of clinical function.42 This novel approach examined the problem of CSM from 
a different perspective and may provide biomarkers in the brain to help predict which patients 
require early intervention. 
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1.2 Magnetic Resonance Imaging 
MRI is an imaging technique that provides anatomic, functional, and physiologic information 
from the body (Figure 1.3). The images provide detailed information from soft tissues that can be 
used for diagnosis, treatment planning, and disease monitoring. 
 
 
Figure 1.3: The 3 Tesla Siemens Magnetom Tim Trio MRI scanner at Robarts 
Research Institute. 
 
MRI is a safe technique that uses magnetic fields and radio-frequency waves to create images. It 
is preferred over CT imaging in many instances as it does not use any form of ionizing radiation, 
and provides more detailed soft-tissue anatomical information. Due to its ability to provide soft-
tissue contrast, particularly between grey and white matter, MRI can be used to investigate the 
central nervous system (CNS) to show areas of injury or demyelination. 	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1.2.1 The MR Signal 
Hydrogen nuclei (protons) found in water and fat in the body are used to produce magnetic 
resonance images.43 Hydrogen is the most abundant nucleus in the human body and found in 
water which makes up 60% of the body weight. The interaction between the hydrogen nuclei and 
the magnetic fields used to produce magnetic resonance images can be explained using a simple 
classical physics description. Briefly, the hydrogen protons have a property called spin, which 
produces a magnetic field. Each hydrogen behaves like a bar magnet where, without any external 
influences, the magnetic fields would be randomly oriented. However, in the presence of a 
magnetic field, such as the one produced by the MRI scanner, a component of the magnetic field 
produced by hydrogen tends to align along the main magnetic field direction of the MRI scanner. 
In the presence of the external magnetic field produced by the MRI, the hydrogen nuclei are all in 
a mixed state that can be decomposed on the basis of two eigenvectors: parallel (low energy 
state) or anti-parallel (high energy state) (Figure 1.4).  
 
 
 Figure 1.4: A) Protons spin in random orientation along their own axis. B) In the  
 presence of a magnetic field, a component of the magnetic field produced by the  
 hydrogen nuclei align either parallel, or anti-parallel to the external field. 
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Protons prefer to be in a low energy state. The number of excess protons in the parallel 
orientation is proportional to the magnetic field where there are 6 per million on a 1.0 Tesla and 9 
per million on a 1.5 Tesla MRI. With higher magnetic field strengths, a larger net magnetization 
occurs, called Mz, which represents the longitudinal component of the magnetization. Higher 
magnetic fields also cause the nucleus to precess faster described by the Larmor Equation:  
ω = γB 
where ω is the precession or the Larmor frequency in MHz, γ is the gyromagnetic ratio, a 
fundamental property of each nucleus (the hydrogen nucleus has a gyromagnetic ratio of 
267.52x106 rad s-1 T-1), and B is the external magnetic field strength in Tesla.  
 
1.2.2 Excitation 
Excitation occurs when energy from an externally applied oscillating magnetic field is absorbed 
by the hydrogen nuclei in a low energy state, elevating them into a high energy state. Usually a 
short burst of energy is used called a pulse. The energy delivered must occur at the resonant 
frequency, typically in the radio-frequency (RF) range, which is determined by the Larmor 
equation. When a RF pulse is applied at the resonant frequency, using a classical description of 
the system, the vector sum of the magnetic moments from the individual hydrogen nuclei (the net 
magnetization) is rotated from it’s equilibrium direction parallel to the static magnetic field of the 
MRI, to produce components that are perpendicular to the main field (the transverse plane). If all 
the magnetization is rotated into the transverse plane, then a 90° RF excitation pulse has 
occurred. In principle, RF excitation pulses can produce any arbitrary rotation (flip angle) of the 
net magnetization. The RF excitation is applied through transmitter coils. The same coils can be 
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used to transmit and receive signals. After the RF excitation pulse is turned off, the spin system 
begins to return to equilibrium.  
 
1.2.3 Relaxation 
To restore the system to equilibrium, the protons in the high energy state must return to the low 
energy state by releasing the same amount of energy that it took for them to become excited. 
When this occurs, the magnitude of the net magnetization that was perpendicular to the main 
static magnetic field decreases and the magnetization along the direction of the main static field is 
restored. Due to the orientation of the coils that are used to detect the MRI signal, only 
magnetization that is perpendicular to the main magnetic field can be detected. The process 
whereby the hydrogen nuclei lose energy and return to equilibrium is called relaxation. The time 
it takes the protons to relax is characterized by two time constants called T1 and T2 relaxation.  
 
T1 relaxation, also known as spin-lattice relaxation, refers to the recovery of the longitudinal 
magnetization as the electromagnetic energy is released as thermal energy into the surrounding 
tissue (lattice). T2 relaxation refers to the dephasing of the spins within the transverse plane. One 
mechanism that causes T2 relaxation is spin-spin interactions, which cause some of the spins to 
precess at different speeds. T1 and T2 relaxation are two independent processes occurring 
simultaneously but at two different rates. In tissue, T2 decay typically occurs 5-10 times more 
rapidly than T1 recovery. T1 relaxation describes recovery of magnetization along the direction of 
the main magnetic field (longitudinal magnetization) while T2 relaxation describes the decay of 
magnetization in the transverse plane.  
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T2* is another time constant used to describe relaxation (or decay) of the signal in the transverse 
plane. T2* occurs due to local inhomogeneities of the magnetic field in addition to spin-spin 
interactions. Therefore, the T2* time constant is shorter than the T2 time constant. It is used to 
produce contrast in tissue in response to changes in local magnetic fields that occur during fMRI, 
as will be further discussed in the next section.  
 
1.2.4 Contrasts 
Different tissues and anatomical structures or pathologies can be identified based on their unique 
relaxation properties. By adjusting image parameters, such as the repetition time (TR) and the 
echo time (TE), images can be weighted to highlight one type of relaxation (e.g. T1-weighted, T2-
weighted, and proton density (PD) weighted (Figure 1.5)). The TR is defined as the time between 
two successive RF (excitation) pulses. The TE is the time between the excitation RF pulse and 
the centre of a magnetization echo produced during measurement. Tissue differences in the rate 
of recovery of the longitudinal magnetization (T1) can be emphasized by using a short TR and a 
short TE. Fat appears bright and fluid appears dark on T1-weighted images. Similarly, tissue 
differences in the rate of dephasing of the transverse magnetization (T2) can be emphasized with 
a long TR and a long TE. Fat appears mid-grey and fluid appears bright on T2-weighted images. 
PD-weighted images are acquired with a long TR and short TE and show the relative water 
concentration in different tissue types.  
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Figure 1.5: The diagram shows the relationship between TR (y-axis) and TE (x-
axis). Different image contrasts can be created by adjusting these imaging 
parameters. Figure adapted from: Huettel SA, McCarthy G, Song AW. Functional 
magnetic resonance imaging. 2nd ed. Sunderland, Mass.: Sinauer Associates; 
2009. 
 
1.2.5 MRI in CSM and SCI 
MRI is a very useful technique in diagnosing CSM as it provides excellent contrast in soft tissue, 
and great anatomical detail of the spinal cord structure. MRI can assess the size and shape of the 
spinal cord in the sagittal and axial plane. It is the preferred method of diagnosing CSM because 
it can be used to visualize soft tissue structures and determine the severity of the spinal cord 
compression, cord oedema, and intrinsic cord abnormalities through signal intensity changes.22,44 
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MRI is the preferred method of imaging for directing diagnosis and surgical management 
because anatomic and spinal cord anatomy can be easily measured and used to identify the 
presence of CSM. Normal cervical spinal canal diameter (C3-C7) ranges from 17 to 18 mm (with 
variation in sexes).45 “Relative stenosis” is diagnosed when the cervical spinal canal diameter 
measures less than 13 mm and “absolute stenosis” with a diameter of less than 10 mm.46-47 A 
congenitally small spinal canal of less than 13 mm is a predisposing factor for CSM.48 Anatomic 
features that deform and narrow the spinal canal, such as osteophytes, loss of disc height, disc 
bulging, ligamentum flavum infolding and ossification of the posterior longitudinal ligament, can 
also be identified. In addition to anatomic characteristics, MRI is useful at determining cord 
properties indicative of CSM, specifically hyperintensity on T2-weighted images or hypointensity 
on T1-weighted images. Worse prognosis has been correlated with signal changes on T2-weighted 
images, indicative of reversible changes in oedema and ischemia or irreversible changes, and/or 
T1-weighted images, suggestive of necrosis, myelomalacia, and cavitation.23-25  
	  
Although these measurements and signal changes allow for a better identification of CSM, they 
are inconclusive in predicting surgical outcome. The debate remains: can canal measurements or 
cord characteristics differentiate the severity of symptoms in patients, and predict who will have a 
better prognosis following surgical intervention? A recent systematic review reported there are 
currently no anatomic factors that are associated with outcome.44 The AOSpine International 
community confirmed these findings with a preliminary survey of 325 members where 87.66% 
members agreed MRI is a good prognostic tool and 83.33% members identified cord 
characteristics as more important than canal measurements.44,49 Even though the cord properties 
are more important in diagnosing CSM, the accuracy of T2 and/or T1-weighted signal changes as 
a predictor of function are highly debated.50-52 Two studies examined the prognostic value of high 
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signal intensity changes on T2-weighted images.50-51 In a prospective study of 70 CSM patients, 
Chibbaro et al. found a significant correlation between a hyperintense signal on T2-weighted 
images and postoperative mJOA score.50 They also found that a hypointense T1-weighted image 
correlated with a lower post-operative mJOA score.50 Setzer et al., on the other hand, reported no 
predictive value of signal intensity changes on T2-weighted imaging and the mJOA scores of an 
“improvement” and a “no-improvement” group following surgery.51 Similarly, Nakashima et al. 
confirmed no significant associations between high signal intensity on T2-weighted imaging and 
the JOA recovery rate or the lower limb function section of the JOA Cervical Myelopathy 
Evaluation Questionnaire (JOACMEQ-L) in a group of 101 CSM patients.53 An important factor 
to keep in mind is that even though the presence of signal changes in T1 or T2 weighted images 
helps in the diagnosis of CSM, there is considerable patient heterogeneity. Patients can be 
asymptomatic but have signal changes on their MRI indicative of SCC. The discrepancy between 
the presentation of symptoms and the imaging markers makes it difficult to predict deterioration 
or success following intervention. New imaging techniques are available that may be more 
sensitive to spinal cord or cortical changes secondary to CSM. These techniques will be 
introduced and discussed in detail in the following sections.  
 
1.3 Functional MRI  
Functional MRI is a technique used to measure brain activity by detecting changes in the MRI 
signal as a consequence of changes in local blood flow and oxygenation. The fMRI technique is 
based on blood oxygen level-dependent (BOLD) contrast that is the result of the coupling 
between cerebral blood flow and neuronal activation.  
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1.3.1 Neurovascular Coupling  
Neurovascular coupling refers to the relationship between neuronal activity and metabolism with 
cerebral blood flow. An increase in blood flow, due to increased neuronal activity, is called 
functional hyperaemia and involves the vascular, astroglial, and neuronal cells of the 
neurovascular unit. Neurons require adenosine triphosphate (ATP) during various processes. 
Neuronal ATP can be synthesized by two main mechanisms: glycolosis or oxidative metabolism 
of glucose. Glycolosis is an anaerobic process that produces a small amount of ATP (2 
molecules) while oxidative metabolism is aerobic and produces large amounts of ATP (36 
molecules). Cerebral metabolism is aerobic and thus requires a constant supply of glucose and 
oxygen, maintained by the cerebral blood flow. During neural activity, the consumption of 
glucose and oxygen triggers an increase in blood flow, which overcompensates for the amount of 
oxygen being extracted (Figure 1.6). The oversupply of the oxygen delivered provides the basis 
for the BOLD signal.53-54 
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Figure 1.6: A) During normal blood flow, oxygen is extracted from the 
hemoglobin at a constant rate. B) During neural activity, the consumption of 
glucose and oxygen triggers an increase in blood flow, which overcompensates 
for the amount of oxygen being extracted. The oversupply of the oxygen delivered 
provides the basis for the BOLD signal. 
 
Neural activity and oxygen metabolism are linked with blood flow, but the details of this 
coupling are still unknown. Several signalling pathways and mechanisms have been implicated. 
The first is a feedback mechanism by which changes to blood flow are directly mediated by 
energy demand.55-57 The response is triggered by various concentrations of ions and metabolic 
by-products such as potassium (K+), nitric oxide (NO⋅), adenosine, carbon dioxide, low levels of 
oxygen, and arachidonic acid.55-57 These ions and metabolic by-products directly or indirectly 
alter the blood flow by activating or inhibiting the vascular smooth muscle cells responsible for 
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vessel diameter.55-57 The second possibility is a feedforward mechanism where neuronal 
signalling occurs through neurotransmitters. This requires astrocytes, glial cells that are ideally 
situated to act as the communication link between the neuronal and vascular systems, to play a 
large role. Astrocytes participate in glutamate uptake and recycling. Glutamate regulates cerebral 
blood flow by increasing intracellular calcium concentrations which in turn activate the arteriole 
smooth muscle cells to dilate or constrict. This mechanism relies on glial pathways as opposed to 
energy consumption. Lastly, the third mechanism involves the direct neuronal innervation of 
smooth muscle cells on the blood vessels themselves. It is likely that these three processes work 
in conjunction to mediate neurovascular coupling.55-57  
 
1.3.2 Hemoglobin 
Hemoglobin is the iron-containing protein molecule responsible for oxygen transport in red blood 
cells. In 1936, Linus Pauling and Charles Coryell discovered that hemoglobin has magnetic 
properties that depend on whether it is bound to oxygen or not.58 Oxygenated hemoglobin (Hb) 
(oxygen molecules bound to hemoglobin) is diamagnetic. It has a magnetic moment of 0 and 
does not differ from other tissues or water when exposed to a magnetic field.58 Deoxygenated 
hemoglobin (dHb), on the other hand, has no oxygen attached, which makes it paramagnetic.58 In 
the presence of a magnetic field, dHb distorts the magnetic field locally by creating microscopic 
field gradients within and around the blood vessels, resulting in T2* based signal loss.57,59 
Consequently, a decreased concentration of dHb leads to a more uniform local magnetic field and 
a longer period of time during which the precessing protons stay in phase. A tissue region with a 
decreased concentration of dHb would therefore have a higher MR signal on a T2* weighted 
image (brighter image pixels) relative to its normal resting state.57,59 This mechanism by which 
dHb modulates MRI signal intensity was termed the BOLD effect. 
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1.3.3 BOLD Contrast 
In the late 1980s, Ogawa and colleagues recognized that the different MRI signal intensities 
produced by the Hb and dHb could be used to measure brain physiology.60 They manipulated 
blood oxygen levels in rats by adjusting the amount of oxygen and carbon monoxide the rats 
breathed.60 They reported a uniform texture with structural differences but few blood vessels on 
T2* contrast images in rats that breathed pure oxygen or carbon monoxide. When the rodents 
breathed normal air, there were areas of signal loss that corresponded to blood vessels. With 
increased levels of dHb (oxygen levels decreased to 0%), the blood vessels became more 
prominent in the T2*-weighted MR images. The results showed that the presence of dHb 
decreased the MR signal on T2* images compared to the presence of Hb. These experiments in 
the 1980s formed the basis for the BOLD contrast.57,60-61  
 
1.3.4 BOLD Hemodynamic Response and Signal Generation 
The hemodynamic response (HDR) refers to the MR signal changes on T2* images triggered by 
neuronal activity.57 Under normal conditions, the Hb is converted at a constant rate to dHb. The 
BOLD effect reflects an intricate relationship between the change in blood flow, blood volume 
and blood oxygenation. Figure 1.7 is a representation of the BOLD hemodynamic response 
described below.  
 
 
 
 
 
23 
 
Figure 1.7: BOLD hemodynamic response. Adapted from: Huettel SA, McCarthy G, Song 
AW. Functional magnetic resonance imaging. 2nd ed. Sunderland, Mass.: Sinauer 
Associates; 2009.  
 
An increase in neural activity requires increased blood flow to the selected brain region to meet 
oxygen and glucose demands. However, some studies have reported a momentary decrease in 
MR signal lasting 1-2 seconds immediately following the onset of neural activity, known as the 
“initial dip.62” This decrease was first reported by Menon and colleagues who suggested that the 
initial dip may reflect initial oxygen extraction localized to the capillaries resulting in a 
temporary increase in dHb.62 This is followed by an increase in blood flow (and supply of Hb) 
and an overcompensatory response to meet the metabolic demands of increased neuronal activity. 
More oxygen is provided than used and this leads to a decrease in the amount of dHb in the 
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selected tissue region and consequently, a decrease in the signal loss due to T2* effects. This 
corresponds to a BOLD signal increase about 2 seconds following the onset of neural activity to 
the peak of the HDR which occurs after about 5 seconds for a short-duration stimulus. During 
longer neuronal activity, the peak may spread into a plateau. Once the activity stops, the BOLD 
signal decreases below baseline in a phenomenon known as the poststimulus undershoot. The 
undershoot occurs because the blood flow decreases more rapidly than blood volume.  
 
1.3.5 fMRI in CSM and SCI  
In clinical applications, maps of cortical regions such as sensory and motor areas can be acquired 
based on the performance of simple tasks. Functional MRI can also be used to identify 
differences in activation between patient populations or to monitor the effects of a 
treatment/intervention in a single population.  
 
The injured brain has the ability to reorganize itself following neuronal loss or axonal injury.63 
Previous fMRI studies have reported cortical reorganization and remodelling in CSM and SCC 
patients as a response to preserve neurological function.42,64-65 Duggal et al. illustrated that 
reversible SCC leads to an increased activated volume within the primary motor cortex (M1) in 
comparison to controls.42 Surgical decompression resulted in cortical reorganization that was 
accompanied by a significant return of clinical function.42 Dong et al. demonstrated altered 
sensorimotor recruitment patterns during wrist and finger movements in 8 CSM patients that 
gained motor function following spinal decompression and recruitment maps similar to that of 
healthy controls.64 Holly et al. reported that CSM patients undergo expanded cortical 
representation for the affected extremity following surgical decompression.65 The exact 
mechanism by which cortical reorganization occurs is not completely understood; but it has been 
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suggested that it may happen due to modification of pre-existing connections and/or the 
development of new circuitry intended to preserve neurological functioning.65 Henderson et al. 
suggested that reorganization may result from growth of new lateral connections, rather than just 
an unmasking of latent pre-existing connections.66 The group studied 20 thoracic complete SCI 
patients and 23 controls while having their hands brushed with a plastic brush.66 SCI resulted in 
medial displacement of auricular finger activation of >13 mm toward the lower body 
representation, the area of the sensory loss.66 The greater the age of the patient and the longer the 
time since injury, the greater the medial displacement of the auricular finger activation.66 
Concomitant to the primary sensory cortex (S1) reorganization, there were associated physical 
changes in the cortical anatomy, suggesting such large movement may be due to growth of new 
connections.66  
 
Freund et al. found similar results where movement of the impaired hand in cervical SCI patients 
showed activation not only in the expected hand area, but in the adjacent leg area.67 The extent of 
activation was predicted by spinal cord atrophy where larger activations were found in patients 
with greater disability.67 In a subsequent study on the same patients, the group hypothesized 
about what the shift represented and suggested two possibilities. The first, similar to past studies, 
that the brain has undergone reorganization where it innervated the neurons in the leg to represent 
inputs from the hand.68 The second possibility suggests an uncontrolled “overflow” of activation 
to the leg area that is prevented in healthy individuals but is not inhibited in SCI because the leg 
has no movement.68 Taken together, these results suggest that cortical plasticity influences 
functional recovery and rehabilitation in response to SCC.  
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Functional MRI has also been instrumental in discovering different adaptive strategies for 
functional compensation following SCI depending on the post-operative stage of recovery.69 
Nishimura et al. compared activation patterns in 20 macaque monkeys at early (1 month) and late 
(>3 months) recovery time points following SCI.69 Based on a precision grip task, there was 
increased activity in the bilateral M1. During the late recovery stage, this activation was further 
increased in the contralesional M1 and extended into the bilateral pre-motor cortex.69 This study 
suggests the brain uses pre-existing neural systems in the early stage by reducing inhibition and 
thus allowing larger activation.69 By the late recovery stage, the brain undergoes plasticity by 
gradually enhancing the original systems or recruiting new ones for functional compensation.69 It 
has also been suggested that an injury to newly developed pathways may be a possible 
explanation for the progressive deterioration observed in a subset of CSM patients.63 But 
previous studies have not separately investigated the patterns of injury and recovery in the motor 
cortex of the mild and moderate CSM patient populations. Such studies could help optimize 
patient selection and aid in determining appropriate care, particularly in cases of early stage, mild 
CSM. 
 
1.4 Diffusion Tensor Imaging 
DTI measures the diffusion of water in tissue and can provide in-vivo information about tissue 
microstructure in healthy and neurodegenerative disease.  
 
1.4.1 Diffusion Weighted Imaging 
In 1827 a botanist named Robert Brown observed pollen grains in water through a microscope 
and found that the pollen particles moved through the water.70 He called it Brownian motion but 
was unable to explain what caused the movement.70 In 1905, Albert Einstein explained the theory 
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behind Brownian motion.71 Brownian motion is the random motion of particles in a fluid due to 
the collisions with the molecules in the fluid.71 Diffusion-weighted imaging (DWI) measures the 
Brownian motion, also known as diffusion, of water molecules due to thermal agitation. 
Magnetic field gradients are used to detect water motion. In DWI, two gradient pulses are 
applied. The first gradient produces a phase offset for each hydrogen nucleus in the sample that is 
dependent on its position. The second gradient pulse attempts to reverse the phase offset 
produced by the first gradient. Hydrogen nuclei within stationary water molecules will experience 
the exact same gradient amplitude both times. The result is that the effect of the two gradient 
pulses will cancel out and no signal attenuation will occur.72 However, hydrogen nuclei in the 
water molecules that move will not be completely refocused after the second gradient pulse is 
applied. These hydrogen nuclei will have a phase offset that is dependent on how far they 
moved.72 Since the MRI signal is equal to the sum of all magnetization components from all 
hydrogen nuclei, the moving water molecules will produce a lower signal than that produced by 
stationary molecules.72 The time between the gradients is called the “diffusion time.”73  
 
1.4.2 Apparent Diffusion Coefficient 
The changes that occur during the diffusion time result in signal attenuation that is proportional 
to the apparent diffusion coefficient (ADC).74 ADC is the measure of water diffusion magnitude74 
or the “rate” of water diffusion.73 It is called “apparent” because it is not possible to measure pure 
diffusion due to the overlaid capillary diffusion and the subject’s gross motion.73 ADC is also 
referred to as mean diffusivity (MD) and calculated from the raw diffusion-weighted images. In 
the body, water molecules diffuse farthest within the diffusion time in tissues with few 
boundaries. This results in greater signal loss, and a darker region on the diffusion weighted 
image.73-74 These areas, such as within the cerebrospinal fluid, will have a higher ADC value and 
28 
appear hyperintense or bright on an ADC map because diffusion can occur in any direction 
without any interruption. Tissues with complex structures and boundaries, such as white matter 
fibers or tumors, appear bright on a DWI image because the water molecules are hindered in their 
movement, there is less diffusion, and consequently less signal loss.73-74 These anisotropic areas 
have a lower ADC and will appear hypointense or darker on an ADC map.  
 
1.4.3 Diffusion Tensor Imaging 
DTI measures the magnitude and direction of water movement. The dephasing and rephasing 
gradient fields are applied as described above, but in at least 6 directions, so a diffusion tensor 
can be calculated. From the diffusion tensor, fractional anisotropy (FA) measures can be 
calculated that provide information about tissue microstructural integrity.75-76  
 
1.4.4 Isotropic and Anisotropic Diffusion 
Measures of FA range from a value of 0 representing isotropy to 1 representing anisotropy 
(unidirectional diffusion).75-76 Isotropic diffusion occurs when water molecules are able to move 
freely in all directions without any boundaries, such as within cerebrospinal fluid (Figure 1.8A). 
Anisotropic diffusion describes water does not diffuse equally in all directions for example the 
movement of water along the long axis of the axon (Figure 1.8B).73,75-76  
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Figure 1.8: A) When motion is unconstrained, as in the large fluid–filled spaces 
deep in the brain (e.g. ventricles), diffusion is isotropic, which means that motion 
occurs equally and randomly in all directions. B) When motion is constrained, as 
in white–matter tracts, diffusion is anisotropic, meaning that motion is oriented 
more in one direction than another. 
 
Diffusion in healthy white matter, whether in the brain or the spinal cord, is predominantly 
anisotropic. White matter consists of tightly packed fiber bundles oriented in a long parallel 
orientation surrounded by axon cellular membranes and myelin sheaths.77 These membranes and 
sheaths act as barriers to water diffusion which forces water molecules to predominantly move in 
the preferred direction: parallel to the white matter fiber rather than perpendicular to it. Injured 
white matter lacks directional organization of the fibers and possibly decreased fiber tract density 
due to axon degeneration, myelin demyelination and/or ischemia (Figure 1.9).74-76 
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Figure 1.9: A) Healthy spinal white matter where the diffusion occurs along the 
long axis of the myelinated tract. B) After spinal cord compression, the white 
matter tracts in the injured area may degenerate and demyelinate, leading to 
functional impairment. Due to the decreased fiber tract density, the FA decreases 
and the ADC/MD increases. Figure adapted from: Ellingson BM, Salamon N, 
Holly LT. Advances in MR imaging for cervical spondylotic myelopathy. Eur 
Spine J 2013 [Epub ahead of print]. 
 
1.4.5 DTI in CSM and SCI 
DTI can be used to determine if white matter tracts have been disrupted or injured due to CSM. 
ADC maps have been shown to be more sensitive than conventional T2-weighted imaging in 
detecting CSM in the spinal cord.78-79 Demir et al. reported higher sensitivity rates of 80% in 
31 
ADC maps compared to 61% in T2-weighted imaging in 26 CSM patients.78 In some cases, 
studies have shown DTI measures are sensitive enough to detect changes in early stages of CSM 
where clinical symptoms are minor. Aota et al. showed ADC maps were able to detect 
abnormalities in early stages of CSM with higher sensitivity rates of 65% compared to 42% using 
T2-weighted imaging.79 Kara et al. used DTI for early detection of CSM in 16 patients without 
hyperintensity on T2-weighted images.80 They found decreased FA at the stenotic level prior to 
any signal intensity changes on the conventional T2-weighted imaging.80 Mamata et al. described 
a subset of CSM patients where slight ADC and FA abnormalities were found at the site of 
compression, in spite of few clinical symptoms present.81 
 
There are also suggestions in the literature that focal changes in FA at the compression site in 
CSM patients may be a useful predictor of myelopathy.82-83 Budzik et al. measured the FA and 
MD in 20 CSM patients at the C2-C3 and compressed level, and 15 controls at the C4-C7 level.82 
The FA was significantly lower at the compressed level in CSM patients and correlated to the 
patients’ clinical scores, suggesting decreased FA may reflect the degree of microstructural 
disorganization of the spinal cord.82 Consistent with this hypothesis, Jones et al. showed patients 
with a higher pre-operative FA at the stenotic level experienced more functional recovery when 
compared to patients with lower FA values.83 These studies implicate FA as a useful biomarker 
for predicting successful outcome following surgery and determining the best surgical candidates.  
 
The interconnectivity of the spinal cord with the cerebral cortex is important since CSM can lead 
to changes in the cortex. More recent SCI studies have acknowledged this intimate relationship 
and have shown that injury to the spinal cord prompts changes upstream in the cortical anatomy. 
Wrigley et al. used voxel based morphometry and DTI in SCI patients to identify structural 
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changes in cortical motor regions and descending motor tracts that may limit motor recovery 
following a SCI.84 The FA was decreased in the cerebral cortex suggesting axonal degeneration 
and demyelination may occur due to growth of new (rewiring) or the unmasking of already 
existing connections.66,85 Henderson et al. found that the greatest region of reorganization in the 
primary somatosensory cortex in thoracic SCI patients, correlated with FA changes.66 The 
reorganization was attributed to changes in cortical anatomy, specifically the growth of new 
lateral connections, because reorganization from the unmasking of already existing connections 
would not change cortical anatomy.66 Similarly, Freund et al. found dissociation between the 
task-related activations during handgrip motions and reduced FA in the M1 leg area of SCI 
patients and proposed subcortical rewiring as a possible mechanism.85 Most importantly, these 
results suggest DTI metrics are able to detect changes upstream from the site of compression and 
may be used as biomarkers for monitoring disease progression or the effects of interventions 
targeting the injured spinal cord. 
 
1.5 Magnetic Resonance Spectroscopy 
MRS can provide metabolic information from different neural structures. An MR spectrum can 
be obtained using any nucleus with a magnetic moment such as phosphorus (31P), fluorine (19F), 
carbon (13C), sodium (23Na) and hydrogen (1H). The most commonly used nucleus is the proton 
(1H) due to its high sensitivity and abundance in the body. In theory, any molecule that contains 
1H may be detected by MRS. In practice, only molecules that are freely mobile (unrestricted) and 
present in high concentration (> 1 mM) can be observed in the brain. The spectrum produced by a 
specific molecule depends on its chemical structure which influences the chemical shift and J-
coupling of the 1H nuclei within the molecule. The concentration of the metabolite can be related 
to the signal intensity of its spectrum.  
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1.5.1 Chemical Shift 
The chemical shift of the 1H nuclei within a molecule determines the position of the peak 
representing the nucleus in the spectrum. As described earlier, when placed in a magnetic field, 
the hydrogen nucleus precesses at a specific frequency determined by the Larmor equation 
(Section 1.2.1). In molecules, the electron cloud surrounding the various hydrogen nuclei shield 
the nucleus and reduce the magnetic field it experiences.86 The greater the density of the electron 
cloud, the greater the shielding experienced by the nucleus, and the greater the reduction in the 
Larmor frequency. The differences in resonance frequency for each hydrogen nucleus give 
information about its molecular group of origin, whether in different molecules or even for nuclei 
on the same molecule but in different positions. The shift in frequency is called the chemical shift 
and is expressed in a dimensionless number: parts per million (ppm). The chemical shift is 
dependent on the strength of the magnetic field and is measured in Hertz87-88 Therefore an 
advantage of using high magnetic field strength is the distance between peaks in a spectrum 
(chemical shift dispersion) increases and allows for more accurate identification of metabolites.87-
88 
 
1.5.2 J-Coupling 
Most metabolites contain multiple hydrogen nuclei and therefore produce multiple peaks in the 
spectrum. In some cases, a nucleus produces a single peak in the spectrum, but some peaks may 
be split into doublets, triplets or multiplets. The internal coupling of nuclei that are separated by 
three or less chemical bonds is called J-coupling or spin-spin coupling and is responsible for the 
peak splitting observed in a spectrum.86,89 The splitting observed in a spectrum can help elucidate 
the molecular structure of a metabolite.86,89 In the absence of coupling, each hydrogen nucleus 
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precesses at a frequency determined by the electronic shielding it experiences (Section 1.5.1). If 
coupled to a nearby hydrogen nucleus then the energy state of that nearby nucleus can modulate 
the electron cloud that is shielding the observed nucleus. This interaction occurs through the 
electron bonds creating a doublet (Figure 1.10).86  
 
 
Figure 1.10: J-coupling occurs due to the interaction of different spins through the electron 
bonds. Uncoupled singlet (A) and coupled spectra with a peak splitting resulting in a 
doublet are shown (B). 
 
Coupling is measured in Hertz and is independent of the external magnetic field strength. If a 
hydrogen nucleus is coupled to more than one other nucleus then triplets, quartets, and more 
complicated multiplets can be formed. 
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1.5.3 Data Acquisition 
In spectroscopy, the signal is obtained from a predefined volume of interest called a voxel. This 
voxel is localized by exciting three orthogonal slices. The intersection of the orthogonal planes 
gives the selected volume of interest (VOI). The signal around the voxel can also be crushed to 
improve spatial selectivity.  
 
Prior to data acquisition, magnetic field uniformity over the VOI is optimized; a process called 
shimming. Shimming corrects for the spatial inhomogeneity of the magnetic field. It is achieved 
by adjusting the current that is going through coils that are designed to produce magnetic fields 
that spatially vary according to specific predefined functions (spherical harmonics). These 
functions include linear and higher order terms. This step can be performed manually or 
automatically. Strong second-order shims correct inhomogeneities in small VOIs while first-
order shim corrections are very effective across large volumes selected for multi-voxel MRS.  
 
The water concentration is approximately 10,000:1 higher than most metabolites in the brain. The 
water signal overpowers the signals from metabolites. The water signal needs to be suppressed in 
order to see the metabolites clearly. A RF pulse designed to excite a narrow frequency band is 
applied. The band is centred at the water peak frequency (~4.7 ppm) so that other metabolites are 
not affected. The water magnetization is tipped into the transverse plane. A crusher gradient is 
then applied to dephase the selected water spins. This method effectively suppresses the water 
peak and the acquisition of the remaining metabolites begins.  
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1.5.4 Spectra 
Each metabolite produces its own “fingerprint” spectral profile. The combination of these 
“fingerprints” results in a spectrum of overlapping peaks. A spectrum is a frequency 
decomposition or a Fourier transform of the acquired time-domain signal.89 The spectrum of the 
resulting metabolites is shown on a graph (Figure 1.11). The x-axis corresponds to the metabolite 
frequency determined by the chemical shift relative to a reference standard (commonly sodium 3-
trimethylsilyl-propionic acid (TSP)) at 0 ppm. For example, in-vivo, the water peak (H2O) is 
centred at 4.7 ppm and the most prominent metabolite peak from N-acetylaspartate (NAA) is 
centred at 2.02 ppm. The y-axis corresponds to the signal magnitude of the metabolite. The 
height of each peak and the area under each peak is proportional to the number of protons 
contributing to the peak (metabolite concentration).89-90  
 
 
 
 
 
 
 
 
 
37 
 
Figure 1.11: The x-axis represents the frequency or chemical shift measured in 
ppm and the amplitude of the peak is on the y-axis. Each peak represents a 
metabolite. The area under the peak is calculated to determine the concentration of 
the metabolite in the voxel. Two examples from a 20 mm isotropic voxel placed 
over the human primary motor cortex are presented that demonstrate large 
differences in NAA concentration (PRESS localization at 3 Tesla , TE=135).  
 
1.5.5 High field MRI/MRS 
There are several advantages of using a high static magnetic field strength (3.0 T and 7.0 T) for 
MR spectroscopy. First, signal-to-noise ratio (SNR) increases linearly with field strength.87-88 An 
increased SNR allows for reduced acquisition time which is very beneficial in a clinical 
setting.86,91 If the examination time is reduced, then several voxels of interest or larger brain 
volumes can be studied.86,91 Second, spectral resolution is improved. This is important because it 
increases the distance between the peaks, making it easier to differentiate and measure the 
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metabolite concentrations.86,91 There are also several disadvantages of high field MRS including 
increased magnetic field inhomogeneity and magnetic susceptibility distortions, particularly near 
air/bone interfaces, increased power deposition, and increased chemical shift artefacts during the 
voxel localization process.  
 
1.5.6 Metabolites 
1.5.6.1 N-Acetylaspartate 
N-acetylaspartate (NAA) produces one of the strongest peaks in the in-vivo brain spectrum at 
2.02 ppm.92 The structure is shown in Figure 1.12. NAA has one of the highest concentrations of 
all free amino acids in the brain (~9.2 mmol/kg in brain tissue).92 NAA is synthesized in neuronal 
mitochondria, then transported into neuronal cytoplasm along axons and broken down in 
oligodendrocytes.86,89 Within a neuron, 75% of NAA is found in the cytosol, and 25% in the 
mitochondria.93 It is found exclusively in neurons of the peripheral and central nervous systems 
in grey and white matter.  
 
 
Figure 1.12: NAA Structure 
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The various functions of NAA are under investigation. It is primarily used as a marker of 
neuronal and axonal viability due to its location in the neurons.94-95 NAA is a marker of cellular 
function because it is synthesized in neuronal mitochondria. It acts as a potential osmolyte 
because it is involved in fluid balance in the brain as a molecular water pump. It is a source of 
acetate for lipid and myelin synthesis in oligodendrocytes. Lastly, it is a precursor for the 
synthesis of the neuronal dipeptide neurotransmitter N-Acetylaspartylglutamate (NAAG).  
 
Absent or reduced NAA may imply neuronal death or neurometabolic impairment.94-95 White 
matter diseases, tumours, chronic stages of stroke, and multiple sclerosis results in decreased 
concentrations of NAA.86 Increased NAA is fairly specific to Canavan disease.86 Several in-vivo 
studies found that NAA levels can reversibly decline after treatment in neurological disorders 
such as epilepsy,96 head trauma,97 and multiple sclerosis.98 Caution must be taken when using 
NAA as a marker of neuronal health because its concentration changes over a person’s life. In 
developing newborns, the NAA is low despite the presence of neurons. The NAA concentration 
rapidly increases as the brain matures, peaking at about 10-15 years of age followed by a slow 
decline over time.99 
 
1.5.6.2 Creatine 
Creatine (Cr) produces two peaks in the in-vivo spectrum at 3.02 and 3.93 ppm. The term Cr in 
this thesis, represents contributions from free Cr and phosphocreatine (PCr) in roughly equal 
proportions. Cr and PCr are found in both gray and white matter, and in other brain cell types 
such as: neurons, astrocytes and oligodendrocytes.100 Cr has an essential role in energy 
homeostasis and is a potential marker of the energy potential available in brain tissues.100 In the 
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presence of ATP, Cr can be phosphorylated to PCr by the enzyme creatine kinase (CK). This 
reaction is reversible and Cr can replenish ATP though the CK reaction. Due to this reaction, Cr 
has been suggested to act as an energy buffer (and ATP reservoir). Some other suggested roles 
include acting as an energy shuttle. ADP and ATP cannot rapidly diffuse across subcellular 
regions whereas Cr/PCr can freely diffuse from energy producing (mitochondria) to energy 
utilizing (myofibril) areas.101 A ratio of PCr and CR can be measured using phosphorus MRS in 
addition to proton MRS in order to acquire additional information about the energy metabolism 
and high-energy phosphate bonds.100 However, we are unable to distinguish between free Cr and 
PCr using proton MRS alone. Total Cr (free Cr and PCr) concentration is indicative of brain 
tissue health and energy homeostasis.  
 
Similarly to NAA, Cr is low in the newborn and then remains increased in adulthood.99 Its 
concentration tends to remain stable in the normal brain due to the high metabolic needs of brain 
tissue cells. Due to its relatively constant concentration, total Cr is often used as an internal 
reference to normalize the signals from the other metabolites and calculate metabolite ratios. 
There are several advantages to calculating ratios. First, they provide a reproducible and sensitive 
measurement and are not prone to errors associated with absolute metabolite level measurements 
such as those attributed to measurement of tissue partial volume and scaling by tissue relaxation 
time constants. Tissue partial volume effects that arise from having different amounts of 
white/grey matter and CSF in selected voxels can be largely avoided with metabolite ratios.102 
Ratios can also be more sensitive in detecting metabolite changes when one metabolite in the 
ratio (e.g. the numerator) increases while another metabolite in the ratio (e.g. the denominator) 
decreases.  
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The main disadvantage of ratios normalized to Cr is that the Cr signal may alter due to 
pathological changes. Cr concentrations are decreased in brain tumors.103 Cr increases have been 
described in gliosis and in MS, due to glial and astrocyte proliferation, respectively.101,104 
Systemic disease may also affect Cr levels in the brain because Cr and PCr are metabolized to 
creatinine which is then excreted by the kidneys.103 If CSM patients with renal disease were 
included in the recruitment for this thesis, then the ratio of a metabolite relative to Cr would be 
altered. For example, a decreased NAA/Cr would normally be attributed to decreases in NAA 
and a stable Cr concentration. In CSM patients with renal disease, a decrease in NAA/Cr could 
represent a decrease in NAA at a faster rate than the decreases in Cr. For this reason, patients 
were excluded if they had any other disease or neurological disorders that could affect Cr, or any 
of the other metabolite concentrations.  
 
1.5.6.3 Choline 
Choline (Cho) has a peak at 3.22 ppm due to nine equivalent protons in three methyl groups. It 
also contains protons that resonate at 3.54 and 4.05 ppm as doublets. However, these have a 
lower intensity and overlap with other resonances making them difficult to detect in-vivo. Cho is 
comprised of: phosphorylated cholines, phosphocholine (PCho), and glycerophosphorylcholine 
(GPCho).89 Cho-containing compounds are found in higher concentrations in myelin and cell 
membranes compared to PCho and GPCho.105 However, Cho-containing compounds are not 
freely movable, are not measurable and do not contribute to the Cho resonance signal at 3.22 
ppm.100 Therefore the main Cho signal is made up of PCho and GPCho. PCho is a precursor for 
membrane synthesis.100 Mainly GPCho and a smaller concentration of PCho are generated during 
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membrane degradation.100 Measures of total Cho are interpreted as a marker of cellular 
membrane turnover.89,100,105 Cho is also found to be a precursor to the neurotransmitter 
acetylcholine.  
 
Elevated Cho can occur due to the accumulation of myelin breakdown products, as found in 
demyelination.100 Cho has also been shown to correlate with the degree of malignancy in 
tumours.86 Increases in Cho may be difficult to interpret because they cannot distinguish between 
the increases observed following infarction (gliosis or ischemic damage to myelin) and 
inflammation (glial proliferation).86  
 
1.5.6.4 Myo-inositol 
Myo-inositol (Myo) is a simple sugar and produces a doublet signal centered at 3.56 ppm. Myo is 
often considered a glial marker because it is synthesized in glial cells, specifically astrocytes.106 
Astrocytes provide neurons with energy, substrates for neurotransmission and are required for 
neuronal repair following injury.107-109 Myo also functions as an osmolyte in astrocytes, which 
means it can efflux from (or enter into) brain cells to preserve the cell volume in response to 
hypotonic (or hypertonic) stress.110-111 Myo is also reported to act as an intermediate in 
membrane and myelin phospholipids metabolism and may represent a product of myelin 
degradation.86,100  
 
Elevated concentrations of Myo can be found elevated in cortical regions of gliosis, astrocytosis, 
and diseases such as Alzheimer’s disease.103 Increased Myo suggests proliferation of glial cells or 
inflammation.103 Gliosis may be associated with neuronal atrophy and/or inflammation of neural 
tissue, thus increases in Myo are often accompanied by decreases in NAA. 
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1.5.6.5 Glutamine and Glutamate (Glx) 
Glutamate (Glu) is the main excitatory neurotransmitter in the brain.89 Glu is a structural 
component in proteins and also involved in energy metabolism.86,89 It is a precursor for glutamine 
(Gln), gamma-aminobutyric acid (GABA) and glutathione.112 Glu and Gln have overlapping 
peaks centered at 2.05 and 2.50 ppm. The discrimination between the two metabolites is reliable 
at 7T MRI but much more difficult at 3T MRI. Therefore, Glu and Gln are often presented as a 
complex called Glx. The Glx resonance signal reflects the total MRS-visible pool of Glu and Gln, 
and minor contributions from GABA, glutathione and other metabolites, available for synaptic 
and metabolic activity.100  
 
Glu and Gln are found intracellularly (in neurons and glial cells) and extracellularly. Once Glu is 
released from neurons into the synaptic cleft, it is taken up by astrocytes.112 Uptake by astrocytes 
prevents excitotoxic damage by maintaining low levels of extracellular Glu.113 Neuronal uptake 
of released Glu is low, but may help sustain the neuronal Glu pool.113 Once Glu is in astrocytes, it 
is degraded or converted to Gln. Gln is the major precursor for neuronal Glu and GABA. Gln is 
then released from astrocytes and is taken up by neurons and converted back to Glu. This process 
is called the Glu-Gln cycle.112 The rate of the Glu-Gln cycle is moderated by neuronal and 
metabolic activity of the stimulated extrasynaptic Glu receptors.112-113 The ratio of Glu in the 
metabolic versus the neurotransmitter pool is a subject of debate. Therefore the Glu 
concentrations measured by MRS, cannot be attributed directly to one specific function. It has 
been suggested, however, that the Glx measured by MRS is most likely related to glutamatergic 
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neurotransmission because Glu cannot pass through the blood-brain barrier  (except in a few 
small areas that have fenestrated capillaries) and must therefore be synthesized in the central 
nervous system.114 Furthermore, Glu and Gln are the building blocks of proteins, but once they 
are bound, they are not visible by MRS. Elevated levels of Gln and Glx have been found in 
hepatic encephalopathy and traumatic brain injury.86,89  
 
1.5.7 MRS in CSM  
MR spectroscopy can be applied to study many disorders as metabolite concentrations can be 
altered in the presence of structural damage (degenerative disorders, gliomas, etc), altered 
physiological conditions (ischemia, etc.) and biochemical or genetic problems.89 MRS has been 
underutilized in the CSM population. One study detected lactate in one-third of their 21 patients 
with CSM and found a significantly lower NAA/Cr ratio at the C2 level of the spinal cord in the 
patient group compared to the control group suggesting axonal or neuronal loss in the spinal 
cord.115 Salamon et al. also measured metabolite changes at the C2 level of 21 cervical 
spondylosis patients separated into two groups, those with and without T2 signal changes, 
compared to 11 healthy controls.116 An elevated Cho/NAA ratio was observed only in the 
spondylosis patients without T2 signal changes while increased Cho/Cr was reported in 
spondylosis patients with and without T2 signal changes.116 These results suggest progression of 
cellular and microstructural changes in the spinal cord as patients progress from asymptomatic to 
severe neurological impairment.116  
 
Only a few studies have focussed on cortical metabolite changes distal to the site of injury. 
Yabuki et al. demonstrated altered metabolite levels in the thalamus of lumbar spine disease.117 
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These patients presented with decreased NAA/Cr and NAA/Cho ratios on the side of the 
thalamus contralateral to the symptoms.117 Similarly, Sharma and colleagues reported decreased 
NAA levels in the primary somatosensory cortex in patients with chronic low back pain 
suggesting altered neuronal-glial interactions that also correlate with the clinical characteristics of 
pain.118  
 
1.6 Goal and Hypothesis 
CSM is a devastating disorder where the spinal cord is compressed and the corticospinal tract is 
compromised. The pathways mediating the efferent and afferent flow of communication between 
the brain and spinal cord are disrupted and alterations within the neural circuits may occur. The 
pathologic changes occurring in the spinal cord due to CSM have been studied extensively, but 
remain relatively unexplored in the cortex. Remote injury of the sensorimotor cortex in patients 
with CSM could be a critical factor in recovery.  
 
The overall goal of this research is to develop biomarkers to predict the outcome of spinal 
decompression surgery that would allow surgeons to optimize treatment plans, especially in early 
stage mild CSM. The goal of this thesis was to characterize the functional, metabolic, and 
structural changes in the primary motor cortex occurring in the CSM patient population using 
advanced MRI methods. We hypothesized that CSM patients who experienced the greatest 
clinical recovery will also demonstrate the greatest ability for cortical adaptation following 
surgery. The specific aims of this thesis are: 
1) To compare metabolite concentrations, specifically N-Acetylaspartate, brain function, and 
white matter integrity in the motor cortex region of CSM patients with healthy controls;  
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2) To determine whether these measures change to normal healthy levels in the primary motor 
cortex following decompressive surgery;  
3) To assess the role of pre-operative imaging biomarkers as potential predictors of surgical 
outcome by correlating them with neurological improvement; and  
4) To characterize imaging differences between the mild and moderate CSM populations prior to 
and following decompressive surgery.  
 
To answer these questions, a single cohort of 28 CSM patients and 11 healthy controls was 
recruited. Each chapter within this thesis presents results obtained from the same patient 
population using advanced MRI techniques.  Each subject participated in two scanning sessions; 
one at baseline and a second session 6 months later. Each MRI session included the acquisition of 
anatomical images, MRS, DTI and fMRI data. CSM patients all underwent spinal decompression 
surgery after the baseline imaging scan. 
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2.1 Abstract: 
Alterations in motor function in cervical spondylotic myelopathy (CSM) secondary to 
degenerative disease may be due to local effects of spinal compression or distal effects related to 
cortical reorganization. This prospective study characterizes differences in metabolite levels in 
the motor cortex, specifically N-acetylaspartate (NAA), creatine (Cr), choline (Cho), myo-
inositol (Myo) and glutamate plus glutamine (Glx), due to alterations in cortical function in 
patients with reversible spinal cord compression (SCC) compared to healthy controls. We 
hypothesized that NAA/Cr levels would be decreased in the motor cortex of CSM patients due to 
reduced neuronal integrity/function and Myo/Cr levels would be increased due to reactive gliosis. 
 
Twenty-four CSM patients and 11 age-matched healthy controls underwent proton-magnetic 
resonance spectroscopy (MRS) on a 3.0 Tesla Siemens Magnetom Tim Trio MRI (Erlangen, 
Germany). Areas of activation from functional magnetic resonance imaging (fMRI) scans of a 
finger-tapping paradigm were used to localize a voxel on the side of greater motor deficit in the 
myelopathy group (n=10 on right side and n=14 on left side of the brain) and on each side of the 
motor cortex in controls. Neurological function was measured with the Neck Disability Index 
(NDI), modified Japanese Orthopaedic Association (mJOA) and American Spinal Injury 
Association (ASIA) questionnaires. Metabolite levels were measured relative to total Cr within 
the voxel of interest.  
 
No metabolite differences were detected between the right side and left side of the motor cortex 
in controls. The CSM patients had significantly decreased neurological function compared to the 
control group (NDI: p<0.001 and mJOA: p<0.001). There was a significant decrease in the 
NAA/Cr metabolite ratio in the motor cortex of the myelopathy group (1.21±0.07) compared to 
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the right (1.37±0.03; p=0.01) and left (1.38±0.03; p=0.007) motor cortex in controls suggesting 
neuronal death or dysfunction distal to the lesion in the spine. No difference was observed in 
levels of Myo/Cr. 
 
Therefore, cortical levels of NAA/Cr may be a meaningful biomarker in CSM, indicative of 
neuronal death or dysfunction.   
 
2.2 Key words:  
cervical myelopathy, magnetic resonance spectroscopy, N-acetylaspartate, functional MRI, motor 
cortex. 
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2.3 Introduction: 
Cervical spondylotic myelopathy secondary to degenerative disease (CSM) is the most common 
type of spinal cord dysfunction in people greater than 55 years of age,1 yet its natural history 
continues to be poorly understood.2 CSM is characterized by the narrowing of the spinal canal 
secondary to disc degeneration and herniation, the development of facet arthropathy and 
ligamentum flavum hypertrophy.2,3 The natural history is typically a gradual deterioration in a 
stepwise pattern with clinical manifestations such as numbness, loss of dexterity, instability and 
bowel and bladder incontinence.2,4 The majority of studies on spinal cord compression focus on 
the local changes in the spinal column or cord and neglect the intimate interconnection with the 
cerebral cortex. 
 
Patients with spinal cord injury (SCI) have shown some degree of functional recovery through 
cortical reorganization and plasticity.2,5-11 In previous work by our group, we demonstrated that 
CSM patients’ had a greater volume of activation in the brain than control volunteers when 
performing a motor task.11 Following decompression surgery, the volume of activation difference 
between the patients and controls increased, suggesting cortical reorganization and recruitment of 
surrounding cortex to perform the motor.11 Similarly, Jurkiewicz et al. suggested the extent of 
movement related activation in the primary motor cortex is strongly associated with the return of 
movement in the upper limbs following SCI.10 Based on these results, our goal was to determine 
if the initial deficits in neurological function experienced by CSM patients were also associated 
with measurable alterations in cortical metabolite levels.  
 
Proton-magnetic resonance spectroscopy (1H-MRS) is a non-invasive method that can repeatedly 
and directly measure levels of relevant metabolites such as N-acetylaspartate (NAA), creatine 
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(Cr), choline (Cho), myo-inositol (Myo) and glutamate plus glutamine (represented together as 
Glx) in the brain. NAA, a marker of neural integrity or viability, is localized to neurons and 
neuronal processes12 and is decreased in several pathological conditions such as Alzheimer’s 
disease, bipolar disease,13 epilepsy,14 post-traumatic stress disorder,15 amyotrophic lateral 
sclerosis,16 multiple sclerosis17-18 and stroke.19 Although the specific role of NAA is still 
unknown, it has been linked to the functional status of the mitochondria and is therefore 
considered a marker of cellular function.20 As a functional indicator, the NAA/Cr ratio has been 
shown to increase in the motor cortex of patients with SCI who experienced functional 
recovery.21  
 
Myo, a sugar primarily found in glial cells, has been associated with gliosis.22 Neuronal loss or 
dysfunction is often accompanied by increased levels of Myo that reflect glial activation or 
proliferation. Zhu et al. reported increases of Myo and Myo/Cr ratio in the grey matter of the 
parietal lobe in Alzheimer’s disease.23 Many other studies have detected increased Myo levels in 
multiple sclerosis24,25 and epilepsy14 while decreased levels have been found in major depressive 
disorder26 and low-grade hepatic encephalopathy.27 
 
The purpose of this study was to determine whether altered metabolite levels are detectable in the 
brain distal to the site of injury in CSM patients using 1H-MRS. We hypothesize that NAA levels 
would be decreased in CSM patients compared to healthy controls due to reduced neuronal 
integrity/function and Myo levels would be increased due to reactive gliosis.  
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2.4 Methods: 
2.4.1 Patient Population 
Twenty-four CSM patients secondary to cervical spondylosis disease were recruited with no 
other neurological disorder such as cerebral palsy, or a history of trauma. Fifty percent of patients 
(n=12/24) were treated for multilevel spondylotic disease and 50% (n=12/24) were treated for 
focal single-level cervical disc herniations causing myelopathy. Patients with CSM had 
symptoms manifesting no longer than a year prior to initial clinic visit. Exclusion criteria 
included any metal implants (aneurysm clips, etc), claustrophobia, pregnancy, nerve root 
symptoms or damage, or any other neurological disorders. CSM was supported by clinical MR 
imaging (Figure 2.1) in all patients. Subjects ranged in age from 32 to 71 years (mean ± standard 
error of the mean; 53 ± 2 years, 16 males, 22 right-handed). The youngest subjects had 
developmental canal stenosis and were carefully assessed prior to inclusion.  
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Figure 2.1: Sagittal cervical spine MR image obtained from a CSM patient with the red 
arrow pointing at the compression. 
 
Eleven subjects of a similar age (46 ± 4 years, 7 males, 11 right-handed) with no previous clinical 
history of CSM or neurological disease were recruited as control subjects. Screening MRI of the 
brain and cervical spine was evaluated by one of the authors (ND) to confirm that there was no 
existing radiographic evidence of cerebral or spinal cord disease, including spinal cord 
compression. All participants gave written informed consent according to the Declaration of 
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Helsinki.28 This study was approved by The University of Western Ontario’s Human Subjects 
Research Ethics Board.  
 
All CSM patients were assessed by the American Spinal Injury Association Impairment 
Classification (ASIA) scale. The maximum motor score is 100 (50 for upper and 50 for lower) 
and the maximum sensory light touch and pin prick was adjusted to test only levels between C2-
T2 and L2-S2 for a total score of 60 for each parameter. All patients and controls completed the 
modified Japanese Orthopaedic Association (mJOA) score as well as patient derived functional 
assessments that include the disease specific Neck Disability Index (NDI).  
 
2.4.2 MRI Acquisition 
All MR data were acquired using a 3.0 T Siemens Magnetom Tim Trio MRI (Erlangen, 
Germany), using a twelve channel head coil with a neck and spine array. Each exam included the 
acquisition of sagittal T1-weighted inversion prepared (Ti = 900 ms) 3D-MPRAGE anatomical 
images (192 slices, 1 mm isotropic resolution, TR/TE = 2300/3.42 ms) covering the entire brain 
to produce high gray matter/white matter contrast. Body coils integrated in the MR scanner were 
used for transmission, while a 12-channel head coil with spine array was used to receive signal. 
Functional MRI (fMRI) was used as a localization tool, to identify the specific region of the 
motor cortex for metabolite level measurement. Each functional brain volume was acquired using 
an interleaved echo-planar imaging pulse sequence (parallel imaging PAT=2, 240x240 
acquisition matrix, 45 slices/volume, 3 mm isotropic resolution, TR/TE = 2500/30 ms, flip angle 
= 90o). The total acquisition time was approximately 5 minutes and 30 seconds for 132 volumes. 
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2.4.3 Activation Paradigm 
The motor pathway was activated during fMRI by instructing the participant to perform finger to 
thumb opposition (“duck quack”) with the right hand followed by the left hand using a button 
box placed on the thumb. Participants were instructed to press the button simultaneously with all 
four fingers followed by an extension upwards to a box surrounding the button. This paradigm 
ensured all participants performed the finger extension to the same angle. The movement rate of 
the repetitive task is known to affect cerebral activation.29-31 To control the frequency of the 
tapping, a block paradigm was designed in which participants received visual cues during 
alternating 30-second intervals of rest and activity. During the activity a visual cue instructed the 
participants to tap every 3 seconds for the 30-second interval. Participants received training prior 
to the fMRI session to reinforce the standardization and reduce learning effects during the 
imaging session. 
 
2.4.4 MRS Acquisition and Analysis 
The anatomical and functional images were used to guide the placement of a 20 mm isotropic 
voxel on the activated region near the “knob” area of the motor cortex.32 Youstry et al. showed 
that neural elements involved in motor hand function are located in a characteristic ‘precentral 
knob’, which is a reliable landmark that identifies the precentral gyrus under normal and 
pathological conditions.32 This landmark along with the location of hand activation in each 
subject was used to ensure consistent voxel placement in each participant. In the CSM group, the 
voxel was placed on the motor cortex contralateral to the side with greater functional deficits 
(n=11 on right side and n=13 on left side of the brain) while control data were acquired from two 
separate voxels placed on each side of the motor cortex. The greater functional deficit was 
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determined based on the objective ASIA score that differentiates between the left and right motor 
and sensory deficits, as well as simply asking the CSM patient which side was worse. Water 
suppressed spectroscopic data were localized using PRESS (TR/TE = 2000/135 ms, 192 
averages, voxel size = 8 cm3, BW = 1200 Hz, 1024 complex points). Any remaining 
unsuppressed water was removed from the spectrum using a Hankel singular value 
decomposition (HSVD) by subtracting resonances between 4.1 and 5.1 parts per million (ppm) 
(water ~4.7 ppm) as determined by the HSVD algorithm.33 
 
Resultant metabolite spectra were fit in the time domain using a Levenberg-Marquardt 
minimization routine incorporating a template of prior knowledge of metabolic lineshapes. The 
analysis software (fitMAN) is incorporated into a graphical user interface written in our 
laboratory in the IDL (Version 5.4 Research Systems Inc, Boulder, CO, USA) programming 
language.34 The acquisition of metabolite prior knowledge data has been previously described in 
detail.33,34 Briefly, high-resolution in vitro spectra were acquired from solutions (pH adjusted to 
7.04) of NAA, Cr, Cho, Myo, Glu and Gln using the same sequence that was used to acquire all 
in vivo data. Each metabolite solution contained sodium 3-trimethylsilyl-propionic acid (TSP) as 
a reference for chemical shift and Lorentzian damping (linewidth). The high resolution 
metabolite spectra were fitted to produce metabolite templates that were subsequently used to fit 
in-vivo spectra. 
 
The metabolites NAA, Cr, Cho, Myo, and Glx (Glu + Gln) were examined based on previous 
studies that have implicated these metabolites in neurological disorders such as SCI and 
CSM,21,35 and since these metabolites could be reliably measured. More specifically, metabolite 
ratios (NAA/Cr, Cho/Cr, Myo/Cr, and Glx/Cr) were calculated and compared between groups. 
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Metabolite ratios relative to Cr provide a reproducible and sensitive measurement and are not 
prone to errors associated with absolute metabolite level measurements such as those attributed to 
measurement of tissue partial volume and scaling by tissue relaxation time constants. Tissue 
partial volume effects that arise from having different amounts of white/grey matter and cerebral 
spinal fluid in selected voxels can be largely avoided with metabolite ratios.36 Ratios can also be 
more sensitive in detecting metabolite changes when one metabolite in the ratio (e.g. the 
numerator) increases while the another metabolite in the ratio (e.g. the denominator) decreases. 
 
2.4.5 Statistical Analysis 
Metabolite ratios were compared between groups using a two-tailed Student’s t-test with alpha 
error of 0.05. Post hoc analyses utilized the Tukey’s test. The Pearson Product Moment 
Correlation Coefficient (r) was used to determine whether there were any correlations between 
metabolite ratios and clinical scores for each group. All statistical tests were two-sided, with 
significance set at the 0.05 level. Corrections for multiple comparisons were not performed 
because this was an exploratory study and we wanted to be sensitive to small metabolite changes. 
mJOA and NDI scores were compared between the CM group and controls using a two-tailed 
Student’s t-test.  
 
2.5 Results: 
2.5.1 Clinical Data 
Table 2.1 lists the demographics and clinical data of the study groups. The groups were not 
different with respect to age (p = 0.158) or sex (p = 0.522). Patients presented with loss of 
dexterity in the hands and gait dysfunction. CSM and control groups had significantly different 
NDI, mJOA and ASIA scores. NDI scores were significantly higher in patients compared to 
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controls (15.8 ± 1.6 and 1.7 ± 0.8, respectively, p < 0.0001). Since a score of 5 or greater is 
required to achieve a classification of mild disability on the NDI scale, the control group in the 
current study was considered to have no disability based on the mean NDI score of 1.7. The non-
zero NDI score of 1.7 in the control group was attributed to minor neck pain. The motor upper 
and lower, sensory upper and sphincter dysfunction segments as well as the mean overall mJOA 
scores were significantly lower in patients compared to controls (p < 0.001). All controls 
recorded a perfect score of 18 on the mJOA questionnaire. As expected, patients had lower ASIA 
scores. There was no significant asymmetry between the right and left side in the motor upper or 
lower scores or in the sensory light touch and pin prick scores. Healthy controls were considered 
to have perfect ASIA scores as no disability was described. 
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Table 2.1: Demographic data and clinical outcome scores for the CSM patient group and healthy 
controls. 
SUBJECT CSM GROUP CONTROLS p-VALUE 
    
N 24 11 n/a 
Age 53 ± 2 46 ± 4 p=0.158 
Sex (Male/Female) 16M/8F 7M/4F p=0.522 
Handedness (Right/Left) 22R/2L 11R/0L p=0.083 
    
NDI    
   Score 15.8 ± 1.6 1.7 ± 0.8 p<0.0001 
    
mJOA Scores    
   Total Score 12.9 ± 0.6 18 ± 0 p<0.0001 
   Motor Upper 3.4 ± 0.3 5 ± 0 p<0.0001 
   Motor Lower 5.1 ± 0.2 7 ± 0 p<0.0001 
   Sensory Upper 1.8 ± 0.2 3 ± 0 p<0.0001 
   Sphincter Dysfunction 2.6 ± 0.1 3 ± 0 p=0.0011 
    
ASIA Scores Right Left   
   Upper Motor 23.2 ± 0.3 23.4 ± 0.6 n/a n/a 
   Lower Motor 23.9 ± 0.4 24.1 ± 0.3 n/a n/a 
   Light Touch 26.2 ± 1.2 26.7 ± 1.1 n/a n/a 
   Pin Prick 25.2 ± 1.2 25.9 ± 1.1 n/a n/a 
     
n/a - not applicable; CSM – cervical spondylotic myelopathy; NDI – Neck Disability Index; 
mJOA – modified Japanese Orthopaedic Association; ASIA – American Spinal Injury 
Association Impairment Classification  
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2.5.2 Magnetic Resonance Spectroscopy 
Magnetic resonance spectra were successfully acquired in all patients and controls. The 
positioning of the MRS voxel is shown as a white box on the motor cortex in Figure 2.2.  
 
 
Figure 2.2: The spectroscopy voxel is outlined in white on coronal (left) and sagittal (right) 
images. The voxel is placed in the motor cortex over the site of finger tapping activation. 
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Figure 2.3 shows the spectrum acquired in one patient along with the fitted result and the residual 
(the difference between the fit and the spectrum). The individual metabolite components for 
NAA, Cho, Cr, Myo, Glu and Gln are also provided in Figure 2.3.  
 
 
Figure 2.3: Top: The result of fitting (green line) is superimposed on the spectrum (red line) 
below the residual line (blue line). Bottom: Individual metabolite components.  
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No differences in any metabolite ratios were detected between the right side (RS) and left side 
(LS) of the motor cortex in the control subjects (p>0.05). Since there were no lateralized 
differences in controls, it was reasonable that metabolite data were combined for all CSM 
patients (10 right side, 14 left side). The average metabolite ratios are shown in figure 2.4 for all 
study groups. There was a significant decrease in the NAA/Cr metabolite ratio in the CSM group 
(1.16 ± 0.07) compared to RS (1.37 ± 0.03; p=0.01) and LS controls (1.38 ± 0.03; p=0.007) in the 
motor cortex. There was no significant difference in the Myo/Cr metabolite ratio in the CSM 
group (0.30 ± 0.02) compared to RS (0.28 ± 0.02; p=0.50) and LS controls (0.31 ± 0.02; p=0.73) 
in the motor cortex. No other metabolite ratio differences were observed. 
 
 
Figure 2.4: Average metabolite ratios of control and CSM groups. The error bars represent 
the standard error of the mean and asterisks (*) represents significant differences between 
the specified groups with p<0.05. 
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Tukey’s post hoc analysis was completed in our exploratory study between CSM patient and 
control groups to determine patterns that were not specified a priori. The patient group was 
divided into two groups based on the side of the brain that was studied. There were no differences 
in metabolite ratios between 13 CSM patients and controls when comparing the left side directly. 
There was a significant decrease in the NAA/Cr (p=0.008), ratio in the 11 CSM patients who had 
the voxel placed on the right side of the motor cortex compared to the RS controls.   
 
2.5.3 Correlations 
There were no significant correlations between any of the metabolite ratio and questionnaire 
scores (p<0.05). There was also no correlation between the duration of symptoms (7.5 ± 1.4 
months) in the CSM group and the NAA/Cr ratio (r=0.008 p=0.48). The presence of spinal cord 
signal change was found in 87.5% (21/24) of the CSM patient group and did not correlate with 
the NAA/Cr ratio (r=0.05, p=0.40). 
 
2.6 Discussion: 
The overall goal of this study was to investigate the effects of cervical spondylotic myelopathy 
on the neuronal metabolism and activity of the motor cortex, specifically, to characterize the 
metabolic correlates of spinal cord compression in the brain. This pilot study is the first to 
perform MRS in the motor cortex to evaluate metabolite levels in patients with reversible spinal 
cord compression. Our findings demonstrated a decrease in the NAA/Cr ratio in the hand area of 
the primary motor cortex in CSM patients compared to healthy controls. Although previous 
studies9,37 have examined local metabolite changes in the spinal cord, our study demonstrated 
altered metabolite levels remote to the site of injury. Remote injury of the sensorimotor cortex in 
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CSM patients could be a critical factor underlying recovery.  
 
Given that cortical synaptic plasticity has been shown in a variety of neurological disorders, we 
focussed our efforts on the metabolite changes in the hand region of the motor cortex instead of 
local changes occurring in the cervical spinal cord. Recent studies have described changes in 
cortical activation during sensory and/or motor tasks in CSM and SCI patients.9-11,38-41 Our group 
has previously reported an increased volume of activation within the primary motor cortex and a 
decreased volume of activation within the primary sensory cortex in CSM patients followed by 
cortical reorganization after decompressive surgery on the spinal cord.11 Based on these results, 
we hypothesized that cortical metabolic changes, particularly changes in NAA/Cr and Myo/Cr, 
may result from spinal cord compression. 
 
The current study found significant decreases in NAA/Cr ratio in the motor cortex of CSM 
patients. Studies into the physiological relationship between NAA and neuronal cells have 
suggested that NAA/Cr is a marker of neuronal density and/or viability.12,20 Reduced NAA/Cr 
may imply neuronal death or neurometabolic impairment.12,20 Additional support for NAA/Cr as 
a neuronal health marker comes from several in vivo studies that found NAA/Cr levels can 
reversibly decline after treatment in neurological disorders such as acute brain injury12 and 
amyotrophic lateral sclerosis.16 The metabolic abnormalities of NAA/Cr detected using MRS 
may precede anatomic degeneration found using structural MRI. 
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Our results of a decreased NAA/Cr ratio are consistent with a previous study by Holly et al. who 
found CSM patients (n = 21) had a significantly lower average NAA/Cr ratio than healthy 
controls at the C2 level of the spinal cord.35 Decreases in NAA/Cr are more likely to be attributed 
to decreases in NAA than increases in Cr, suggesting axonal or neuronal damage/loss. It remains 
controversial whether neuronal damage, as suggested by NAA levels, is permanent or reversible 
in the setting of incomplete injury secondary to degenerative spinal cord compression. Puri et al. 
performed 1H-MRS on the motor cortex of the dominant hand/cortical hemisphere unless motor 
function was lateralised, in which case the weaker side was assessed, in 6 patients recovering 
from incomplete SCI and 5 healthy controls.21 They found the NAA/Cr ratio was higher in the 
motor cortex of recovering patients than of the motor cortical area in controls.21 These results 
have clinical implications in determining the role of potential surgery. If it is confirmed that 
increases in NAA/Cr accompany recovery in CSM patients after the initial decrease as observed 
in our study, MRS could provide a non-invasive method for prognosis and monitoring of CSM 
patients. 
 
We found no significant change in the Myo/Cr ratio. Myo regulates osmotic pressure in 
neuroglial cells and is found specifically in astrocytes.42-44 It has been shown to increase in 
neurodegenerative diseases such as Alzheimer’s disease45 and multiple sclerosis24,25 and is 
considered a glial marker. Astrocytes provide neurons with energy, substrates for 
neurotransmission and are required for neuronal repair following injury.42-44 However they can 
also suppress repair43,44 by forming a scar and producing molecules that inhibit re-growth of 
damaged or severed axons.44 In SCI, a glial scar may act as a local barrier to the regeneration of 
damaged axons.43,44,46 Lebrun-Julien et al. disrupted the signalling events surrounding retinal 
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glial cells and found they could protect the majority of neurons and confirmed that glial cell 
events play a key role in death triggered by glutamate.47 The lack of any changes with Myo may 
indicate that reversible spinal cord compression does not trigger glial activation and proliferation 
in the motor cortex. Glial activation and scarring may only occur in the setting of irreversible 
neuronal cell death.  
 
Past research has found more than 60% of CSM patients have a T2 signal change in the spinal 
cord on MR imaging.48,49 Spinal cord signal change is most commonly found in the more severe 
CSM and can be associated with changes such as myelomalacia.50 The presence of signal 
intensity changes on MRI has been suggested as a possible criterion for surgery.51,52 Even though 
the presence of spinal cord change was found in 87.5% of the CSM subjects in this study, there 
was no correlation with the decrease in NAA/Cr. The lack of correlation could be suggestive of a 
disconnect between significant spinal cord injury and the neuronal integrity or viability in the 
motor cortex.  
 
We hypothesized that there may be correlations between changes in the NAA/Cr and Myo/Cr 
metabolite ratios and the neurological functional scores. However no significant correlations 
were observed between any metabolite ratios and the NDI, mJOA or ASIA questionnaires. Since 
the NAA/Cr ratio was significantly decreased in the patient group and the clinical scores were 
also found to be significantly worse in the patient group, the lack of a correlation between the 
metabolite ratio and clinical scores suggests that functional changes may be dominated by the 
local insult to the cord, not damage to the cortex. Future work will determine whether alterations 
in the cortex correlate with or limit functional recovery following spinal decompression surgery. 
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2.6.1 Limitations 
Stringent inclusion criteria, along with rigorous acquisition and post-processing methods are 
required to reduce data variance. Our pilot study included a sample size of 24 patients, with an 
attempt to select a homogenous population of patients with a similar clinical history. We 
performed high magnetic field MRS at 3.0 T, which provides greater signal-to-noise ratio and 
greater spectral separation of multiplets that tend to overlap at lower field strength.53,54 A larger 
cohort will be necessary to determine whether MRS findings have prognostic significance. 
Prospective studies should include patients with both short and long term pathology to determine 
how cortical metabolite levels are altered during the course of CSM. Other regions of the motor 
cortex may also be of interest. A limitation of our study was that spectra were acquired only from 
the contralateral motor cortex of the weaker side in CSM patients rather than on both sides as 
done in the control subjects. Spectroscopy data were only acquired from a single side in patients 
due to time constraints as patients could not tolerate the long scan times required to obtain 
spectroscopy data from both sides. The pooling of spectroscopy data in the patient group from the 
side of the motor cortex with the greatest functional deficit as previously described21 was a 
reasonable approach as lateralized spectroscopy measurements in the control group did not show 
metabolite level differences. However, future studies would benefit from lateralized spectroscopy 
measurements in CSM patients to evaluate potential heterogeneity, and correlation of metabolite 
level changes in the cortex with findings on cervical MRI.  
 
2.7 Conclusion: 
This study demonstrates decreased NAA/Cr in the motor cortex of patients with CSM, indicating 
the presence of neurological damage or dysfunction likely caused by neuronal and/or axonal 
injury. 
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CHAPTER 3: 
METABOLITE CHANGES IN THE PRIMARY MOTOR CORTEX AFTER SURGERY 
IN CERVICAL SPONDYLOTIC MYELOPATHY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
State of Publication: Aleksanderek I, McGregor SM, Stevens TK, Goncalves S, Bartha R, 
Duggal N. Metabolite Changes in the Primary Motor Cortex After Surgery in Cervical 
Spondylotic Myelopathy. In preparation for submission. 
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3.1 Abstract: 
N–Acetylaspartate (NAA), an indicator of neuronal mitochondrial function, is decreased in the 
motor cortex of patients with cervical spondylotic myelopathy (CSM). This decline may impact 
response to therapy. The goals of this study were to characterize longitudinal metabolite 
alterations in the motor cortex following decompression of the spinal cord using 1H magnetic 
resonance spectroscopy (MRS) and evaluate white matter (WM) integrity with diffusion tensor 
imaging (DTI).  
 
Twenty–eight CSM patients had two separate 3.0 Tesla MRI scans before and six months 
following surgery. Ten healthy controls underwent two MRI scans six months apart. Metabolite 
levels normalized to creatine (Cr) were measured from the motor cortex contralateral to the 
greater functional deficit side in the patient group and on both sides in controls. Fractional 
anisotropy (FA) and mean diffusivity (MD) were measured by DTI in the WM adjacent to the 
motor and sensory cortices of the hand and the entire cerebral WM.  
 
In CSM patients, NAA/Cr levels were significantly lower six months following surgery 
(1.48±0.08; p<0.03) compared to pre-operative levels (1.73±0.09), despite significant clinical 
improvement in questionnaire scores. The FA and MD were the same between the patient and 
control groups in all measured regions at all time points, suggesting WM integrity is unaffected. 
 
NAA/Cr levels decreased in the motor cortex in CSM patients six months following successful 
surgery. Intact WM integrity with decreased NAA/Cr levels suggests mitochondrial metabolic 
dysfunction persists following surgery.  
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3.3 Introduction: 
Cervical spondylotic myelopathy (CSM) represents a common and unique model of incomplete 
spinal cord injury (SCI) that is potentially reversible, providing an opportunity to examine the 
mechanisms involved in injury, recovery, and neuronal plasticity. Surgical intervention in CSM 
patients does not always provide consistent results, as patients may improve, remain static or 
even deteriorate after surgery.1-3 Recently, our group employed functional magnetic resonance 
imaging (fMRI) to demonstrate cortical reorganization in the sensorimotor cortices in spinal cord 
compressed (SCC) patients prior to and after spinal decompression surgery.4 To understand why 
recruitment of adjacent cortex was necessary post surgery in the setting of clinical improvement, 
we utilized proton magnetic resonance spectroscopy (1H–MRS) in a second study to examine the 
metabolic alterations occurring in the primary motor cortex of CSM patients compared to 
controls.5 CSM patients had  lower N-acetylaspartate (NAA) to creatine (Cr) ratio, suggesting 
significant neuronal dysfunction upstream of injury site.5 Functional decline in CSM may also 
involve alterations in white matter (WM) tract integrity measured by diffusion tensor imaging 
(DTI). However, until now, the potential for remote changes in the WM integrity of the brain 
have not been considered.  
 
The goal was of this study was to follow the CSM patient population longitudinally to assess how 
metabolic changes and fibre tract integrity of the primary motor cortices correlate to clinical 
outcomes in the context of recovering neurological function following surgery.  
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3.4 Methods: 
3.4.1 Patient Population 
Twenty-eight patients (age 51 ± 2 years, 21 males, 26 right–handed) with a clinical history of 
CSM of less than or equal to one year and no other neurological disorders were recruited and 
participated in two 3.0 Tesla MR imaging sessions. Pre–operative clinical assessment involved 
patient history, neurological examination and radiological studies with x–rays and MRI. Surgery 
for the treatment of symptomatic CSM was considered when there was a history of progressive 
neurologic deficits (motor weakness, numbness, gait dysfunction, bowel and bladder 
dysfunction), concordant imaging with evidence of SCC, and limited or no response to 
appropriate conservative measures. CSM patients underwent a baseline research MRI scan, 
surgical decompression surgery, and then a second research MRI scan six months post–surgery. 
Ten subjects of similar age (48 ± 4 years, 5 males, 10 right–handed) with no previous evidence of 
SCC and no history of neurological disease were recruited as controls. Control subjects had two 
MRI sessions six months apart without surgical intervention. Informed written consent was 
obtained for all procedures and the study was approved by the Western University Human 
Subjects Research Ethics Board. All patients and controls completed validated instruments for 
assessing disability resulting from myelopathy such as the modified Japanese Orthopaedic 
Association (mJOA) outcome measure, in addition to the American Spinal Injury Association 
Impairment Scale (ASIA), and the Neck Disability Index (NDI).   
 
3.4.2 MRI Acquisition 
All MR data were acquired using a 3.0 T Siemens Magnetom Tim Trio MRI (Erlangen, 
Germany), using a twelve channel head coil with a neck and spine array. Before imaging, an 
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automated global shimming procedure using first- and second-order shims optimized the 
magnetic field over the brain. The imaging exam, which lasted between 80-90 minutes in total, 
included the acquisition of sagittal T1-weighted inversion prepared (TI=900 ms) 3D-MPRAGE 
anatomical images (192 slices, 1 mm isotropic resolution, TR/TE=2300/3.42 ms) that covered the 
entire brain and produced high contrast between gray and white matter.  
 
3.4.3 MR Spectroscopy Acquisition and Analysis 
The anatomic images were used to guide the placement of a 20 mm isotropic voxel near the 
“precentral knob” area of the primary motor cortex (Figure 3.1).6 The “knob” area is a reliable 
landmark that identifies the neural elements associated with motor hand function.6 The voxel was 
placed on the motor cortex contralateral to the side with greater functional deficits in the CSM 
patient group (n=12 on right side and n=16 on left side) while controls had a separate voxel 
placed on each side of the motor cortex.  
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Figure 3.1: The spectroscopy voxel is outlined in white on anatomical images. 
 
Water suppressed and unsuppressed spectroscopic data were acquired using the Point-Resolved 
Spectroscopy sequence (PRESS, TR/TE=2000/135 ms, suppressed: 192 acquisitions; 
unsuppressed: 8 acquisitions; voxel size=8 cm3). Spectra were processed and fitted using custom 
built in-house software called fitMAN.7 The analysis software (fitMAN) is incorporated into a 
graphical user interface written in our laboratory in the IDL programming language (Version 5.4 
Research Systems Inc, Boulder, CO, USA). Initial post-processing involved combined 
QUALITY deconvolution to restore the Lorentzian lineshape and eddy current correction.7-9 
Following lineshape correction, any remaining unsuppressed water signal was removed from the 
spectrum using a Hankel singular value decomposition (HSVD) that required no prior 
knowledge. All unsuppressed water signal was removed by subtracting resonances between 4.1 
and 5.1 parts per million (ppm, water ~4.7 ppm) as determined by the HSVD algorithm.9 
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Resultant metabolite spectra were fitted in the time domain using a Levenberg-Marquardt 
minimization routine that utilized prior knowledge templates of metabolic lineshapes. The 
acquisition of metabolite prior knowledge data has been previously described in detail.7,9 The 
metabolites NAA, Cr, choline (Cho), myo-inositol (Myo), and glutamine plus glutamate (Glx) 
were examined based on previous studies that have implicated these metabolites in neurological 
disorders such as SCI and CSM.10,11 More specifically, metabolite ratios (NAA/Cr, Cho/Cr, 
Myo/Cr, and Glx/Cr) were calculated and compared as this approach removes the potential for 
tissue partial volume errors and may be more sensitive to metabolite changes. 
 
3.4.4 DTI Acquisition and Analysis 
Diffusion weighted scans of the brain were acquired using a spin-echo echo-planar imaging (EPI) 
sequence (75 slices, iPAT=3, TR/TE=10000/83 ms, b-value=0 s/mm2 and 1000 s/mm2) 
incorporating 30 diffusion encoding directions. Diffusion data were analyzed using Brain 
Voyager QX v2.2. A diffusion-weighted magnetic resonance image and a volumetric magnetic 
resonance image were defined for each subject.12 The volumetric magnetic resonance image was 
used to strip the skull and create a mask of the brain to avoid processing background noise. The 
diffusion-weighted magnetic resonance image was then co-registered with the volumetric 
magnetic resonance image. A volume diffusion weighted image was generated and subsequently 
used, along with the previously created mask, to calculate the FA and MD for each pixel. 
Regions of interest (ROI) were defined for each subject in the WM adjacent to the motor and 
sensory cortices of the hand in both right and left cerebral hemispheres (RM, LM, RS, LS; Figure 
3.2). A new ROI was defined for each patients and control at each visit.  
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Figure 3.2: Regions of interest used for DTI analysis. Yellow and blue regions depict WM 
adjacent to the left and right primary motor cortices, respectively. Pink and green regions 
depict the WM adjacent to the left and right primary sensory cortices, respectively. The 
darker green is shown to indicate the boundaries of the cerebrum WM region. 
 
The motor cortex was identified by the “precentral knob” area as documented by Youstry et al. to 
ensure consistent ROI placement in each participant.6 The WM immediately adjacent to this 
portion of the neocortex was included (Figure 3.2). For the motor cortex, the “knob” was 
identified on axial images and the location was confirmed with the omega or horizontal epsilon 
sign location moving from the inferior to the superior slice. The entire omega sign was 
highlighted and extended up to the grey matter of the precentral sulcus. Medially, the motor 
cortex ROI extended in a straight line connecting the medial aspects of the precentral and central 
sulci, and extended equal distances laterally. The sensory cortex was demarcated as the gyrus 
directly posterior and surrounding the ‘precentral knob’ and ROIs were selected below the 
neocortex of that gyrus. The WM was selected on the VMR images. The cerebellum and spinal 
cord were not included when examining the entire cerebral WM.  
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3.4.5 Statistical Analysis 
All data are presented as the group mean followed by the standard error of the mean. An 
unpaired Student’s t-test was used for cross-sectional comparisons of imaging and functional 
measures between the CSM patients and controls at each time point. In the CSM patients, the pre- 
and post-surgery metabolite concentrations, FA and MD values, and questionnaire scores were 
compared using a paired Student’s t-test. Paired t-tests were also used to evaluate measurement 
reproducibility in the control group. All statistical testes were two-sided, with significance set at 
an alpha level of 0.05. 
 
3.5 Results: 
3.5.1 Clinical Data 
The patient and control groups were not different with respect to age, sex or hand dominance 
(p>0.05; Table 3.1). Nineteen of 28 CSM patients (68%) underwent 1–level surgery and 9 (32%) 
had 2–level surgery. From initial scan, the average follow-up time was 194 days (± 9) for CSM 
patients and 176 days (± 15) for the controls. The mean overall modified Japanese Orthopaedic 
Association (mJOA) score improved in the CSM patient group following surgery (13.0 ± 0.5 pre–
operatively compared to 15.9 ± 0.3 following surgery; p<0.0001). Six months following surgery, 
CSM patients exhibited higher ASIA scores and less neck pain, demonstrated by lower NDI 
scores (Table 3.1). All controls recorded a perfect mJOA score of 18 and no disability captured 
by the ASIA and NDI scores during both visits (p<0.05). 
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Table 3.1: Demographic and clinical data for the CSM patient group and healthy controls (mean 
± standard error of the mean). 
Subject CSM Controls p-value 
    
N 28 10 -- 
Age (years) 51 ± 2 48 ± 4 0.45 
Sex (Male/Female) 21M/7F 5M/5F 0.22 
Hand Dominance (Right/Left) 26R/2L 10R/0L 0.08 
Side of Worst Symptoms (Right/Left) 12R/16L -- -- 
Surgery    
   1 level 19 (68%) -- -- 
   2 level 9 (32%) -- -- 
Follow-up time (days)    
   Surgery (CSM) or baseline 
   (controls) and 6 month scan 194 ± 9 176 ± 15 0.28 
mJOA Score    
   Pre-op 13.0 ± 0.5 18 ± 0 p<0.0001 
   Post-op 15.9 ± 0.3 18 ± 0 p<0.0001 
    
CSM Patients Pre-op Score Post-op Score p-value 
    
mJOA Score – Total 13.0 ± 0.5 15.9 ± 0.3 p<0.0001 
   Motor Upper Extremity 3.4 ± 0.3 4.6 ± 0.1	   0.0001 
   Motor Lower Extremity 5.2 ± 0.2	   6.1 ± 0.2 0.0002 
   Sensory Upper Extremity 1.7 ± 0.1  2.3 ± 0.1 p<0.0001 
   Sphincter Dysfunction 2.6 ± 0.1 2.8 ± 0.1 0.09 
    
ASIA Impairment Score  196.0 ± 4.4 213.5 ± 2.0 0.0009 
    
NDI Score 16.7 ± 1.6  9.3 ± 1.4 0.0001 
CSM – cervical spondylotic myelopathy; mJOA – modified Japanese Orthopaedic Association; 
ASIA – American Spinal Injury Association Impairment Scale; NDI – Neck Disability Index 
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3.5.2 Magnetic Resonance Spectroscopy 
Magnetic resonance spectra were successfully acquired in all CSM patients and controls. No 
differences in any metabolite ratios were detected between the right side and left side of the 
motor cortex in the control subjects (p>0.05) at either time point. Since there were no lateralized 
differences in controls, we combined the metabolite data for all CSM patients (12 right side, 16 
left side).5,10 Control metabolite ratios have been described previously.5 There were no changes in 
any of the metabolite ratios in the control group over time (p>0.05).  
 
Following spinal decompression surgery, the NAA/Cr ratio significantly decreased in the CSM 
patients (1.73 ± 0.09 pre-operatively compared to 1.48 ± 0.08 post-operatively; p=0.03; Figure 
3.3). There was no change in the Choline/Creatine (Cho/Cr), Myo-inositol/Cr (Myo/Cr) or 
Glutamine plus Glutamate/Cr (Glx/Cr) ratios over time (Figure 3.3).  
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Figure 3.3: Average metabolite ratios for the CSM patients at pre and post-operative time 
points (asterisks represent significance differences). Error bars represent standard error of 
the mean.  
 
3.5.3 Diffusion Tensor Imaging 
Sixteen CSM patients and eight healthy controls were included in the DTI analysis. Subjects 
were excluded due to incomplete DTI acquisition (n=3) related to patient discomfort, 
misalignment of the diffusion tensor data on the anatomical images due to motion (n=3) or when 
no DTI scan was performed (n=8). CSM patient and control results are reported in Table 3.2. Pre-
operatively, the FA and MD measurements were not statistically different between the CSM and 
control groups in any motor or sensory regions studied (p>0.05). There were also no significant 
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differences in FA or MD in any regions including the entire cerebrum following surgery (p>0.05) 
in CSM patients (Table 3.2).  
 
Table 3.2: Average FA and MD (± standard error of the mean) data for the CSM patient and 
control groups in the specified regions of interest. (* indicates significant difference between 
groups or following surgery, p<0.05). 
 
Right Motor Left Motor Right Sensory Left Sensory 
Entire 
Cerebrum 
      
Baseline FA      
    CSM  0.40 ± 0.01 0.41 ± 0.01 0.31 ± 0.01 0.32 ± 0.01 0.43 ± 0.01 
    Controls 0.38 ± 0.02 0.39 ± 0.02 0.31 ± 0.01 0.32 ± 0.02 0.43 ± 0.01 
      
Follow-up FA      
    CSM  0.40 ± 0.004 0.41 ± 0.004 0.30 ± 0.01 0.32 ± 0.01 0.42 ± 0.01 
    Controls 0.39 ± 0.01 0.40 ± 0.01 0.29 ± 0.01 0.30 ± 0.02 0.41 ± 0.01 
      
Baseline MD      
    CSM  0.23 ± 0.01 0.23 ± 0.01   0.28 ± 0.01 0.27 ± 0.01 0.23 ± 0.01 
    Controls 0.24 ± 0.01 0.24 ± 0.01 0.27 ± 0.02 0.27 ± 0.02 0.23 ± 0.002 
      
Follow-up MD      
    CSM  0.23 ± 0.004 0.23 ± 0.004 0.29 ± 0.01 0.27 ± 0.01 0.23 ± 0.003 
    Controls 0.23 ± 0.001 0.23 ± 0.01 0.28 ± 0.01 0.28 ± 0.01 0.24 ± 0.003 
      
CSM – cervical spondylotic myelopathy; FA – fractional anisotropy; MD – mean diffusivity   
 
3.6 Discussion: 
This study is the first to perform longitudinal MRS and DTI in the brain to determine whether 
metabolite concentrations and water diffusion characteristics in CSM patients are associated with 
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functional improvement following surgery. Six months following surgery, a decrease in NAA/Cr 
concentration was observed in the hand area of the primary motor cortex, despite a significant 
improvement in neurological function. There was no change detected in the water diffusion 
characteristics within the surrounding WM. Intact WM integrity with decreased NAA/Cr 
concentration suggests mitochondrial metabolic dysfunction rather than axonal damage occurs in 
the primary motor cortex. Therefore the functional improvement observed after six months may 
result from brain reorganization and recruitment of surrounding cortex as suggested by previous 
studies, rather than the reversal of cellular metabolic abnormalities.  
 
The most striking finding in the current study was that NAA/Cr concentrations decreased in the 
motor cortex even though CSM patients experienced clinical recovery after surgery. NAA is an 
amino acid that is present at very high concentrations in the brain and has one of the strongest 
signals in the magnetic resonance spectrum at 2.02 ppm.13,14 NAA is synthesized in the 
mitochondria of neurons, transported into the cytoplasm and then along the course of the axons.14 
Since it is found exclusively in neurons, it has become an important marker of neuronal density, 
integrity,13,14 and mitochondrial dysfunction.13 A decrease in NAA/Cr does not necessarily imply 
irreversible neuronal injury or death.15 The results of the current study suggest that despite 
neurological recovery following surgical intervention a further decrease in NAA/Cr in the motor 
cortex also occurs. Metabolite levels did not recover as expected in concordance with reversible 
SCC and functional improvement. 
 
Neuronal repair may occur by resolution of inflammation, remyelination and possibly cortical 
adaptation.16 Duggal et al. has shown that the motor cortex recruits adjacent cortex in response to 
surgical intervention in SCC patients.4 Dong et al. reported similar adaptations in sensorimotor 
97 
cortices that accompany clinical deterioration and a significant return of clinical function 
following surgery.17 Freund et al. demonstrated increases in the BOLD response during a 
repetitive handgrip task, not only in the hand area, but also in the leg area of the primary motor 
cortex.18 The primary motor cortex may have limited capacity for metabolic recovery and may 
provide functional recovery by brain reorganization as a compensatory mechanism. If this is the 
case, strategies to improve clinical outcomes should be targeted equally to the recruited adjacent 
cortex in addition to the recovery of the primary motor cortices.   
 
The potential role of axonal injury in mediating decreased NAA/Cr concentration in the motor 
cortex following surgical intervention was evaluated by diffusion tensor imaging. Axonal 
integrity is one factor that can be inferred by FA and MD measurements.19 An increase in FA 
suggests an increase in density, more coherent organization, or greater myelination of fibers;12 
while a decrease indicates Wallerian degeneration, local extracellular edema, smaller number of 
fibers, or axonal loss.20,21 In contrast, MD is a measure of the ease of water movement and 
declines with increasing tissue barriers and increases in structural lesions, demyelination, and 
axonal loss.22,23 The preservation of FA and MD values has been interpreted as protection or 
maintenance of axonal integrity.24,25 Previous studies have demonstrated that retrograde 
Wallerian degeneration and the disruption of WM tracts, specifically the corticospinal tract, was 
less evident as the distance increased from the site of injury in the cervical spine.26,27 Our DTI 
results suggest intact cortical connectivity with complete preservation of axonal integrity in the 
brain. Similar results were found in the setting of irreversible SCI where James et al. identified a 
population of axons that survived but remained chronically unable to function under normal 
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physiological conditions.28 Our results suggest dysfunction of neuronal mitochondria in the motor 
cortex, and provide a potential target for future therapeutic interventions. 
 
3.6.1 Limitations 
Our study included stringent inclusion criteria, along with rigorous acquisition and post-
processing methods to reduce data variance. We performed high magnetic field MRS at 3.0 T, 
which provides greater signal-to-noise ratio and greater spectral separation of multiplets that tend 
to overlap at lower field strength.29,30 One limitation of our study was that spectra were acquired 
only from the contralateral motor cortex of the weaker side in CSM patients rather than on both 
sides as was performed in the control subjects. Spectroscopy data were only acquired from a 
single side in CSM patients due to time constraints as patients could not tolerate the long scan 
times (80-90 minutes) required to obtain spectroscopy data from both sides in addition to other 
imaging parameters. The pooling of spectroscopy data in the patient group from the side of the 
motor cortex with the greatest functional deficit as previously described5,10 was an acceptable 
approach as lateralized spectroscopy measurements in the control group did not show metabolite 
level differences. Future studies would benefit from lateralized spectroscopy measurements in 
CSM patients to evaluate potential heterogeneity, and correlation of metabolite level changes in 
the cortex with findings on cervical MRI.  
 
3.7 Conclusion: 
NAA/Cr ratios were decreased in CSM patients 6 months following surgical intervention. 
Together with constant FA and MD values indicating maintenance of axonal integrity, the 
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decreases in NAA/Cr suggest neuronal mitochondrial impairment. Our findings of a clear 
neurological improvement in CSM patients following surgery support the hypothesis that 
neurological recovery may necessitate the recruitment of surrounding cortex, given that focal 
recovery in the motor cortex may be metabolically unattainable. Future studies will investigate 
the possible role for NAA as a predictive marker for clinical improvement during pre-operative 
screening.   
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CHAPTER 4: 
MILD AND MODERATE CERVICAL SPONDYLOTIC MYELOPATHY: ARE THEY 
METABOLICALLY AND FUNCTIONALLY DIFFERENT? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
State of Publication: Aleksanderek I, Stevens TK, Goncalves S, Bartha R, Duggal N. Mild and 
moderate cervical spondylotic myelopathy: Are they metabolically and functionally different? In 
preparation for submission. 
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4.1 Abstract:  
The ideal timing of surgical intervention for CSM patients with early, mild symptoms, remains 
particularly controversial since select patients can stabilize clinically without operative 
intervention. Proton magnetic resonance spectroscopy (MRS) has demonstrated altered 
metabolite levels in the primary motor cortex of CSM patients suggesting mitochondrial 
impairment. In addition, functional MRI (fMRI) studies have demonstrated cortical 
reorganization in response to spinal cord compression and surgery. The goal of this study was to 
compare the recovery of neuronal metabolism and functional reorganization in the primary motor 
cortex between people with mild and moderate CSM following surgical intervention.  
 
Twenty-eight CSM patients had two separate 3 Tesla MRI scans that included MRS and fMRI 
before and six months following surgery. The classification of CSM was based on  neurological 
and functional disability measured using the modified Japanese Orthopaedic Association (mJOA) 
questionnaire. Specifically, mild CSM was defined by a mJOA score of >12 out of 18 (n=15) and 
moderate CSM by a score of 9-12 (n=13). Ten healthy controls underwent two MRI scans six 
months apart. Metabolite levels were measured in the motor cortex on the greater deficit side in 
the patients and on both sides in the control subjects. Motor function was assessed in patients and 
controls using a right finger-tapping paradigm. Significant differences in metabolite ratios and 
functional activation between the control, mild CSM, and moderate CSM groups at pre- and post-
operative time points were identified. Paired t-test was used to detect the effects of surgery on the 
CSM group.  
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Mild CSM patients had a lower pre-operative N-acetylaspartate to creatine (NAA/Cr) ratio, 
suggesting mitochondrial dysfunction, compared to moderate CSM patients. Following surgery, 
NAA/Cr in the moderate CSM group decreased to the levels observed in the mild CSM group. 
The mild group had a larger functional volume of activation (VOA) in the primary motor cortex 
than moderate CSM group prior to surgery. Following surgery, the VOAs were comparable 
between the mild and moderate CSM groups and had shifted towards the primary sensory cortex.  
 
NAA/Cr levels and the size of the VOA in the motor cortex can be used to discriminate between 
mild and moderate CSM. Following surgery, the metabolic profile of the motor cortex did not 
recover in either group, despite significant clinical improvement. We propose metabolic 
impairment in the motor cortex necessitates recruitment of healthy cortex to achieve functional 
recovery. 
 
4.2 Key words:  
cervical spondylotic myelopathy, functional MRI, magnetic resonance spectroscopy, N-
Acetylaspartate, brain plasticity 
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4.3 Introduction: 
The ideal timing of surgical intervention for patients with mild cervical spondylotic myelopathy 
(CSM) remains controversial. CSM occurs secondary to degenerative changes in the cervical 
spine resulting in compression of the spinal cord.1-3 CSM can present abruptly with severe 
symptoms of neurological impairment or insidiously with a slow, stepwise deterioration.1,4 
Natural history studies have shown that these symptoms can improve, decline or stay stable with 
conservative treatment.5,6 Surgical intervention is recommended for patients who fail to respond 
to conservative treatment and continue to deteriorate. However, the benefits of surgery in CSM 
patients with mild symptoms are controversial as some studies suggest that these patients can also 
stabilize if treated conservatively.7-11 In contrast, recent reports suggest that surgery results in 
improved functional, disability-related, and quality-of-life outcomes at 1 year in symptomatic 
CSM, even when the disease was mild.12  
 
Recent work by our group has demonstrated that CSM produces metabolic and functional 
changes in the brain.13,14 Specifically, decreased N-acetylaspartate (NAA) to creatine (Cr) ratio 
was observed in the primary motor cortex of CSM patients suggesting mitochondrial impairment. 
Functional MRI studies have also demonstrated cortical reorganization in response to spinal cord 
compression and surgery.14 This collective evidence reveals that the brain, distal to the site of 
injury, adapts and compensates for the compression of the cervical spinal cord.  
 
Biomarkers must be developed to help optimize the selection of CSM patients for surgical 
treatment, particularly in cases of early stage, mild CSM, where it has been shown that a 
prolonged duration of symptoms may be associated with a poor surgical outcome.15 Previous 
studies have not compared the patterns of injury and recovery in the motor cortex of mild and 
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moderate CSM patient populations. MRI changes within the spinal cord, including the presence 
of high-signal intensity changes on T2-weighted images, do not reliably correlate with 
neurological function or predict post surgical outcomes.9,16-19 Therefore, the goal of this 
longitudinal study was to compare the distinct metabolite and functional profiles in the primary 
motor cortex (M1) of mild and moderate CSM patients before and after decompressive surgery. 
We hypothesized that the reduction of NAA/Cr levels and functional impairment in M1 would be 
greater in moderate CSM compared to mild CSM, and the that moderate CSM would show the 
greatest change following surgery.  
 
4.4 Methods: 
4.4.1 Patient Population: 
Twenty-eight patients with CSM were recruited. Each patient participated in two 3.0 Tesla MR 
imaging sessions, pre-operatively and 6 months following decompressive surgery. Ten healthy 
subjects with no history of neurological disorders were also recruited and underwent two MRI 
scans, six months apart. Participants were not excluded based on the use of any medications. 
Informed written consent was obtained and the study was approved by The University of Western 
Ontario Human Subjects Research Ethics Board. Each patient and control completed the disease 
specific modified Japanese Orthopaedic Association scale (mJOA) at each visit. The mJOA scale 
ranges from 0 to 18 points (with 18 representing the maximum score) and identifies upper and 
lower motor, upper sensory, and sphincter function.20 Mild CSM (n=15) was defined as having a 
mJOA score of >12, while moderate CSM (n=13) patients presented with a mJOA score between 
9 and 12 at the initial visit.21 There were no severe CSM cases recruited in this study (mJOA 
<9).21 
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4.4.2 Anatomical Data Acquisition: 
All MR data were acquired using a 3.0 T Siemens Magnetom Tim Trio MRI (Erlangen, 
Germany), using a twelve channel head coil with a neck and spine array. Each exam included the 
acquisition of sagittal T1-weighted inversion prepared (TI = 900 ms) 3D-MPRAGE anatomical 
images (192 slices, 1 mm isotropic resolution, TR/TE = 2300/3.42 ms) that covered the entire 
brain and produced high gray matter/white matter contrast.  
 
4.4.3 MRS Data Acquisition and Analysis: 
Before imaging, an automated global shimming procedure using first- and second-order shims 
was performed to optimize the magnetic field over the imaging volume of interest. The hand area 
of the motor cortex was identified by the “knob” as described by Youstry et al. to guide the 
placement of a 20 mm isotropic voxel.22 This “precentral knob” area is a reliable landmark that 
identifies the motor hand function in the precentral gyrus under normal and pathological 
conditions.22 The voxel was placed on the motor cortex contralateral to the greater deficit side in 
the CSM patient group (n=12 on right side and n=16 on left side) while controls had a separate 
voxel placed on each side of the motor cortex.  
 
Spectroscopic data were acquired using the Point-Resolved Spectroscopy (PRESS) acquisition 
sequence (TR/TE =2000/135 ms, suppressed: 192 averages; unsuppressed: 8 averages; voxel size 
= 8 cm3) and post-processed by combined QUALITY deconvolution23 to restore the Lorentzian 
lineshape and eddy current correction.24-27 Following lineshape correction, any remaining 
unsuppressed water was removed from the spectrum using a Hankel singular value 
decomposition (HSVD) that required no prior knowledge. All unsuppressed water signal was 
109 
removed by subtracting resonances between 4.1 and 5.1 parts per million (ppm) (water ~4.7 ppm) 
as determined by the HSVD algorithm.26 
 
A Levenberg-Marquardt minimization routine incorporating a template of prior knowledge of 
metabolite lineshapes was used to fit the resultant metabolite spectra in the time domain. The 
analysis software (fitMAN) is incorporated into a graphical user interface written in our 
laboratory in the IDL programming language (Version 5.4 Research Systems Inc, Boulder, CO, 
USA).24 The acquisition of metabolite prior knowledge data has been previously described in 
detail.25,26 The metabolites NAA, Cr, choline (Cho), myo-inositol (Myo), and Glutamine plus 
Glutamate (Glx) were examined based on previous studies that have implicated these metabolites 
in neurological disorders such as spinal cord injury (SCI) and CSM.13,28,29 Ratios (NAA/Cr, 
Cho/Cr, Myo/Cr, and Glx/Cr) were calculated and compared between groups. Metabolite level 
ratios were measured relative to Cr because this removes the potential for tissue partial volume 
errors and may be more sensitive in detecting metabolite changes. 
 
4.4.4 Functional MRI Data Acquisition and Analysis: 
Each functional brain volume was acquired using an interleaved echo-planar imaging pulse 
sequence (parallel imaging iPAT=2, FOV = 240x240 mm, 80x80 acquisition matrix, 45 
slices/volume, 3 mm isotropic resolution, TR/TE = 2500/30 ms, flip angle = 90o). 
 
The motor pathway was tested during fMRI by instructing the participants to perform finger to 
thumb opposition (“duck quack”) in the right hand. Briefly, participants were instructed to press a 
button placed on their thumb simultaneously with all four fingers followed by an extension 
upwards to a box surrounding the button. The box ensured each participant lifted their fingers at 
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the same angle by touching the top of the box prior to the next tap. The movement rate of the 
repetitive task is known to affect cerebral activation,30-32 therefore a standard block design was 
used in which participants received visual cues during alternating 30-second intervals of rest and 
activity. During the activity a visual cue instructed the participants to tap every 3 seconds for the 
30-second interval. Participants received training prior to the fMRI session to reinforce the 
standardization and reduce learning effects during the imaging session. 
 
Image analysis was completed using BrainVoyager QX (Brain Innovation B.V., Maastricht, The 
Netherlands, http://www.brainvoyager.com). Anatomic images were transformed to Talairach 
space for group analysis.33 Preprocessing of functional images included 3D motion correction 
using trilinear/sinc interpolation where only data images with small motion-related effects (< 2 
mm movement) were included. To improve signal-to-noise and reduce the effect of intersubject 
structural differences, spatial smoothing was performed by convolving each slice with a 6 mm 
FWHM Gaussian filter. Next, slice scan time correction and linear trend removal were 
completed. Functional data were then registered to the anatomical images in Talairach space and 
a 4D volume time course file was created for each subject.  
 
A general linear model (GLM) and random-effects analysis (RFX) were used to create individual 
and group statistical parametric maps of brain activation and set to a threshold of p<0.05. A 
boxcar function coincident with the paradigm with a double-Gamma hemodynamic response 
function was used as a predictor of the fMRI response to the motor task. ANOVA tests were used 
to identify significant clusters of activation between groups at each time point (controls versus 
mild CSM versus moderate CSM). ANOVA tests were set to a threshold using a corrected value 
of p<0.001 for multiple comparisons using the False Discovery Rate (FDR). For all contrasts, a 
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VOA, corrected p-value, and Talairach coordinates of the center of gravity (COG) of the 
activation were examined. Talairach Daemon Client 2.0 (University of Texas Health Science 
Center, SAN Anotnio, TX) was used to convert the Talairach coordinates to their corresponding 
Brodmann areas.  
 
4.4.5 Statistical Analysis:  
All data are presented as the group mean followed by the standard error of the mean (SE). The 
mJOA scores were compared between mild and moderate groups using a two-tailed Student’s t-
test at both time points. The Student’s t-test was also used to identify the significant differences 
in metabolite ratios between the controls, mild CSM, and moderate CSM groups at pre- and post-
operative time points. Next, a paired t-test was used to detect the effects of surgery on the CSM 
group.  
 
The Pearson Product Moment Correlation Coefficient (r) was used to determine whether 
metabolite ratios were correlated with clinical scores, and whether the change in metabolite ratios 
were correlated with the change in the clinical scores in each group. In this pilot study no 
corrections were made for multiple comparisons. The change in a parameter value was calculated 
by subtracting the pre-operative value from the post-operative value. All statistical tests were 
two-sided, with significance set at an alpha level of 0.05. 
 
4.5 RESULTS: 
4.5.1 Clinical Data: 
We recruited fifteen mild CSM patients with a mean age of 50.1 (± 3 years; 13 males) and 
thirteen moderate CSM patients with a mean age of 53.0 (± 2 years; 8 males). Ten healthy 
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controls of similar age were recruited (48 ± 4 years, 5 males). The average follow-up times were 
188 ± 16 days, 201 ± 18 days and 176 ± 15 days for the mild CSM, moderate CSM, and controls, 
respectively. The three groups did not differ with respect to age, sex or follow-up time (Table 1). 
The mild and moderate CSM groups did not differ in their duration of self-reported symptoms or 
the presence of signal change at the site of compression on T2-weighted images (Table 1).  
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Table 4.1: Demographic and clinical data for the CSM patient group and healthy controls (mean 
± SE). 
Subject Mild CSM  Moderate CSM Controls 
    
N 15 13 10 
Age (years) 50.1 ± 3 53.0 ± 2 48 ± 4 
Sex (Male/Female) 13M/2F 8M/5F 5M/5F 
Hand Dominance (Right/Left) 13R/2L 13R/0L 10R/0L 
Duration of symptoms (months) 7.9 ± 2.1 8.6 ± 1.5 -- 
Signal change on T2-weighted 
image at site of compression 14/15 10/13  
Surgery    
     1 level 12 (80%) 7 (54%) -- 
     2 level 3 (20%) 6 (46%) -- 
Follow-up time (days)    
Surgery (CSM) or baseline 
(controls) and 6 month scan 
188 ± 16 201 ± 18 176 ± 15 
    
mJOA Score    
     Pre-op 15.1 ± 0.3 10.6 ± 0.1 18 ± 0 
     Post-op 16.3 ± 0.3 15.4 ± 0.5 18 ± 0 
 
CSM – cervical spondylotic myelopathy; mJOA – modified Japanese Orthopaedic Association 
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In the 6 months following surgery, the mJOA scores increased for all CSM patients except one 
who had a decrease of 1 point. Mild CSM patients with an average pre-operative mJOA score of 
15.1 ± 0.3 improved to 16.3 ± 0.3 post-operatively (p=0.002). The moderate CSM group 
increased their average mJOA scores from 10.6 ± 0.4 pre-operatively to 15.4 ± 0.5 post-
operatively (p<0.0001). The mild and moderate CSM groups were significantly different pre-
operatively (p<0.0001) but recovered to the same post-operative score (p=0.14) (Figure 1). All 
controls recorded a perfect mJOA score of 18 at both visits. 
 
 
Figure 4.1: Mean pre- and post-operative mJOA questionnaire scores for the mild and 
moderate CSM patient groups. A perfect score of 18 represents no dysfunction. (Error bars 
represent the SE, * represents significance p<0.05). 
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4.5.2 Control Metabolic Profile: 
The control group presented with no changes in any of the metabolite ratios over time: NAA/Cr 
(baseline 1.91 ± 0.04, follow-up 1.90 ± 0.07; p=0.89), Cho/Cr (baseline 0.31 ± 0.01, follow-up 
0.32 ± 0.01; p=0.66), Myo/Cr (baseline 0.30 ± 0.01, follow-up 0.29 ± 0.02; p=0.79), and Glx/Cr 
(baseline 0.59 ± 0.02, follow-up 0.62 ± 0.04; p=0.58). 
 
4.5.3 Mild CSM Metabolic Profile:  
The pre-operative NAA/Cr ratio of 1.55 ± 0.13 did not change following surgery (1.44 ± 0.09; 
p=0.50), but was significantly decreased compared to the controls at pre (p=0.02) and post-
operative (p=0.0004) time points (Figure 2). The pre-operative Cho/Cr ratio of 0.27 ± 0.01 did 
not change following surgery (0.27 ± 0.01; p=0.97), but was significantly decreased compared to 
the controls at pre (p=0.01) and post-operative (p=0.03) time points (Figure 3). Mild CSM has a 
pre-operative Myo/Cr ratio of 0.35 ± 0.03 which significantly dropped following surgery to 0.23 
± 0.03 (p=0.006, Figure 4). The post-operative Myo/Cr was significantly lower in mild CSM 
compared to controls (p=0.049, Figure 4). The remaining ratio of Glx/Cr did not change six 
months post-operatively and was not different from control values. 
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Figure 4.2: Average NAA/Cr metabolite concentrations in the controls at baseline and 6-
month follow-up, and mild CSM, and moderate CSM groups prior to and following surgery 
(error bars represent the SE; * represents significance p<0.05). 
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Figure 4.3: Average Cho/Cr metabolite concentrations in the controls at baseline and 6-
month follow-up, and mild CSM, and moderate CSM groups prior to and following surgery 
(error bars represent the SE; * represents significance p<0.05). 
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Figure 4.4: Average Myo/Cr metabolite concentrations in the controls at baseline and 6-
month follow-up, and mild CSM, and moderate CSM groups prior to and following surgery 
(error bars represent the SE; * represents significance p<0.05). 
 
4.5.4 Moderate CSM Metabolic Profile: 
Moderate CSM patients presented with a pre-operative NAA/Cr ratio of 1.94 ± 0.08 which 
significantly decreased to 1.51 ± 0.11 (p=0.03) post-operatively (Figure 2). The post-operative 
NAA/Cr was significantly lower in moderate CSM compared to controls (p=0.01, Figure 2). The 
remaining ratios of Cho/Cr, Myo/Cr and Glx/Cr did not change six months post-operatively and 
were not significantly different from the control values (Figures 3 and 4). 
 
4.5.5 Mild CSM versus Moderate CSM: 
There are two important distinctions between mild and moderate CSM patients. First, mild CSM 
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presented with a much lower pre-operative NAA/Cr ratio compared to moderate CSM (p=0.02, 
Figure 2). Following surgery, the NAA/Cr ratio in moderate CSM decreased such that the mild 
and moderate CSM patients had a similar NAA/Cr ratio (Figure 2). Second, mild and moderate 
CSM had a similar pre-operative Myo/Cr ratio. Post-operatively, the Myo/Cr ratio significantly 
decreased in the mild group and became lower than that observed in moderate CSM (p=0.02), 
and in controls (Figure 4).  
 
4.5.6 Metabolite Ratio Correlations to Clinical Function: 
There were no significant correlations between any metabolite ratios and clinical questionnaires 
in mild and moderate CSM. 
 
4.5.7 Motor Function Assessed by fMRI: 
Pre-operatively, mild CSM patients had a larger VOA (Figure 5) compared to moderate CSM 
(p=0.05; min cluster size=118; COG (27, -42, 58), left parietal lobe, postcentral gyrus, BA 5). 
Following surgery, the VOAs centered around BA 3 in mild and moderate CSM did not differ 
significantly (mild CSM: FDR<0.001; p<0.000014; COG (38, -30, 53); left parietal lobe, 
postcentral gyrus, BA 3 and moderate CSM: FDR<0.001; p<0.000006; COG (37, -28, 54); left 
parietal lobe, postcentral gyrus, BA 3). There was an increase in the VOA in moderate CSM 
following surgery using an uncorrected p-value, however the change did not reach the threshold 
for significance after FDR correction (Figure 5). The controls did not significantly differ between 
the two visits in the VOA and location (p>0.05).  
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Figure 4.5: The corrected volume of activation for the mild CSM (left) and the moderate 
CSM (right) patients groups are shown. The pre-operative activation is displayed in the top 
row showing the mild CSM group had significantly larger activation near the primary 
motor cortex compared to the moderate CSM group. Following surgery, both groups had 
equal activation volume shifted towards BA 3, the primary somatosensory cortex. The 
moderate CSM patients showed an increase in the VOA after surgery using an uncorrected 
p-value, however this increase did not remain significant following FDR correction. 
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4.6 Discussion: 
The overall goal of this study was to compare and contrast the effects of mild and moderate CSM 
on the neuronal metabolism and functional activity of M1. The need for surgical intervention for 
patients with clinical evidence of mild CSM has become increasingly controversial. Our findings 
demonstrated a lower NAA/Cr ratio in the hand area of M1 in mild CSM patients compared to 
healthy controls and moderate CSM patients. Following successful surgery and despite clinical 
improvement, NAA/Cr levels did not recover in mild CSM. The moderate CSM patients, which 
had significantly worse pre-operative mJOA scores and demonstrated the largest interval 
improvement following surgery, demonstrated a decline in NAA/Cr levels following surgery.  
 
In conjunction with evaluation of tissue metabolism, functional MRI was used to evaluate motor 
cortex function prior to and following surgery. Prior to surgery, in the setting of low NAA/Cr 
levels in the mild CSM group, but normal NAA/Cr levels in the moderate CSM group, we found 
a larger VOA within the sensorimotor cortex of mild CSM compared to moderate CSM. 
Consistent with a previous study showing greater M1 activation in CSM patients compared to 
controls,14 our fMRI findings suggest that the mild CSM group has recruited surrounding cortex 
to enhance motor task performance prior to surgery. In the moderate CSM group following 
surgery, functional improvement was accompanied by decreased NAA/Cr while the fMRI 
measured VOA equalized to that observed in the mild CSM group. These distinct patterns of 
remote injury of the sensorimotor cortex in mild and moderate CSM patients could underlie the 
natural history of the disease and be used to determine the timing and need for intervention. 
These results also suggest that therapies designed to enhance brain plasticity could provide 
functional benefits to CSM patients both prior to and following surgery.34-37 
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This study is the first to describe a clear distinction between mild and moderate CSM with 
respect to pre-operative NAA/Cr concentrations in the motor cortex. NAA has one of the highest 
concentrations of all free amino acids in the brain and is found primarily in the neurons of the 
central nervous system.38,39 It is considered to be a marker of neuronal density and/or 
viability.40,41 Reduced levels of NAA/Cr imply neuronal loss or metabolic impairment in the 
neuronal mitochondria.39 We previously reported decreased NAA/Cr levels in the motor cortex of 
CSM patients compared to healthy controls.13 Holly et al. also found a decreased NAA/Cr ratio at 
the C2 level of the spinal cord in CSM patients suggesting axonal or neuronal loss.29 In the 
current study, the measured NAA/Cr levels were lower in mild CSM compared to moderate 
CSM, suggesting that metabolic impairment in the neuronal mitochondria may be a feature 
associated with mild functional impairment. Previous work has shown that decreased 
mitochondrial function can lead to synaptic dysfunction42-44 that may in turn trigger cortical 
reorganization and recruitment of healthy regions in the primary sensory cortex (S1).44 This 
process could explain why neurological function was better preserved in the mild CSM group at 
baseline; these patients were able to recruit adjacent cortex as indicated by a larger VOA at 
baseline compared to the moderate CSM patients. This result is also consistent with a previous 
study that found that patients with SCC had an increased VOA within the motor cortex in 
comparison to controls.14 In contrast, the moderate CSM group, which had normal NAA/Cr 
levels, but profound neurological deficits pre-operatively, demonstrated small VOAs. This 
evidence suggests that the moderate CSM group had a limited compensatory ability for 
reorganization, accounting for the poor neurological scores prior to surgery.  
 
Following surgery, both the mild and moderate CSM patients demonstrated interval functional 
improvement. However, a larger improvement was observed in moderate CSM, where six 
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months following surgery, both groups had a mJOA score reflecting mild neurological disability.  
Surgical intervention did not reverse the low NAA/Cr levels in the mild CSM group, nor did it 
preserve the normal levels of NAA/Cr in the moderate CSM group. Interestingly, the Myo/Cr 
ratio decreased significantly in the mild CSM group following surgery suggesting reduced glial 
activity, altered glial metabolism, or a loss of astrocytes.45 Decreased Myo/Cr levels have 
previously been associated with decreased gliosis in major depression.46-48 The Cho/Cr ratio 
remained low in mild CSM compared to controls following surgery suggesting continued 
abnormal membrane metabolism.49  
 
In light of the low NAA/Cr ratio in mild CSM and the decrease in the NAA/Cr ratio observed in 
moderate CSM six months after surgery, adaptive plasticity in response to mitochondrial and 
synaptic dysfunction is a possible explanation for the observed neurological recovery. The 
observed increase in the VOA in moderate CSM (prior to FDR correction) is consistent with this 
notion. Prior studies have also shown that neurological recovery following surgical 
decompression is associated with cortical reorganization.14,34,35 Specifically, surgery for spinal 
cord compression resulted in cortical reorganization that was accompanied by a significant return 
of clinical function.14 Dong et al. also demonstrated altered sensorimotor recruitment patterns 
during wrist and finger movements in eight CSM patients that gained motor function following 
spinal decompression and recruitment maps similar to that of healthy controls.35 Similarly, Holly 
et al. reported that CSM patients undergo expanded cortical representation for the affected 
extremity following surgical decompression.34 The exact mechanism by which cortical 
reorganization occurs is not completely understood, but it has been suggested that it may occur 
by modification of pre-existing connections and/or the development of new circuitry intended to 
preserve neurological functioning.34 Stroke patients have also presented with spontaneous 
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recovery that occurs due to cortical plasticity with the best recovery resulting from reorganization 
in the damaged hemisphere.36,50-51 In the current study, one possible explanation for the posterior 
shift in activation is that the corticospinal axons originating in S1 are preserved since they are 
less vulnerable to injury than the axons originating in M1. This advantage exists because the S1 
fibres run more medial and posterior in the spinal cord.35,52 Future studies should include 
metabolite level measurements in both the M1 and S1 cortices to evaluate potential changes in 
NAA due to the reorganization.  
 
4.7 Conclusion: 
CSM is a unique condition of reversible spinal cord injury that can be exploited to understand the 
link between brain metabolic dysfunction and synaptic activity and remodelling. The current 
study found distinct metabolic and functional profiles in the motor cortex that discriminate 
between mild and moderate CSM patients prior to surgery. Following surgery, the NAA/Cr ratio 
in the motor cortex decreased significantly in moderate CSM but was accompanied by 
neurological improvement and a brain activation volume that equalled that observed in mild 
CSM patients. We propose mitochondrial dysfunction, indicated by low levels of NAA/Cr, is the 
primary trigger for cortical reorganization and recruitment leading to functional improvement. 
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CHAPTER 5: 
GENERAL DISCUSSIONS, LIMITATIONS, FUTURE DIRECTIONS AND 
CONCLUSIONS 
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5.1 General Discussions 
CSM is a devastating disorder resulting in a wide array of symptoms ranging from mild, 
numbness or subtle problems with dexterity, to severe, such as quadraparesis and incontinence. 
The pathways mediating the efferent and afferent flow of communication between the brain and 
spinal cord are disrupted and alterations within the neural circuits may occur. A large amount of 
current research has concentrated on the local changes occurring in the spinal cord. This thesis 
provides new knowledge of advanced non-invasive MRI techniques used to explore the 
functional, metabolic, and structural changes of the primary motor cortex changes of CSM 
patients in the context of injury and recovery.  
 
Chapter 2 describes the result of the first study to measure metabolite concentrations in the 
primary motor cortex of CSM patients. The following clinical and metabolic profile was 
established: CSM patients had decreased neurological function, and decreased NAA/Cr 
concentration in the primary motor cortex compared to healthy controls. This study concluded 
that CSM patients undergo pathophysiological changes in the cortex, remote to the site of injury, 
and that MRS is a sensitive technique that can detect these alterations. Furthermore, the NAA/Cr 
decreases suggested neuronal damage or dysfunction, and proposes the use of NAA as a future 
biomarker.  
 
Chapter 3 details the first longitudinal study that used MRS and DTI to investigate the metabolic 
alterations and fibre tract integrity involved in injury and recovery in CSM patient population 
undergoing decompressive surgery. In previous studies, our group has utilized fMRI to 
demonstrate cortical reorganization in SCC patients prior to and following surgical 
decompression. To understand why recruitment of adjacent cortex was necessary post surgery in 
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the setting of clinical improvement, MRS and DTI were utilized to measure the potential for 
remote changes in the metabolite concentrations and WM integrity of the brain. The most striking 
finding is that NAA/Cr concentrations decreased in the motor cortex in the context of clinical 
recovery after surgery, suggesting metabolic dysfunction persists following surgery. The intact 
WM integrity with decreased NAA/Cr concentration suggests mitochondrial metabolic 
dysfunction rather than axonal damage occurs in the primary motor cortex. This study provided 
crucial information that the brain does not metabolically recover following successful surgery. 
The neurological recovery may be attributed to brain reorganization and recruitment of 
surrounding cortex, rather than the reversal of cellular metabolic abnormalities.  
 
Chapter 4 characterizes the use of MRS and fMRI to create objective biomarkers that will help 
stratify CSM patients along a spectrum of injury severity and recovery. The following distinct 
profiles were established: In mild CSM, the metabolic profile of the motor cortex did not recover, 
despite successful surgery and clinical improvement. The mild CSM group also had a larger 
activated region in the primary motor cortex than moderate CSM prior to surgery. The moderate 
CSM patients, who were more severely impaired prior to surgery, demonstrated the largest 
interval improvement following surgery and a drop in NAA/Cr levels post-operatively. Following 
surgery, the activated areas were comparable between the mild and moderate groups and had 
shifted towards the primary sensory cortex. This study establishes that it is possible to 
differentiate between the mild and moderate CSM groups using clinical examination and 
advanced imaging biomarkers. These distinct patterns of remote injury of the sensorimotor cortex 
in mild and moderate CSM patients could be a critical factor underlying natural history and 
determining the timing and need for intervention. 
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The ultimate goal was to develop advanced imaging biomarkers that could be used to assess the 
severity of CSM and predict the outcome of decompressive surgery. This work identified the 
application of new imaging techniques in examining the prognostic ability of MRS, DTI and 
fMRI. This data can be used to more accurately identify a specific point in injury severity that 
will have the most benefit from surgical intervention. Furthermore, the use of NAA as a 
biomarker may be useful in providing prognostic information to patients, and in implementing 
appropriate treatment plans, especially in early stage mild CSM.  Equally important in this work, 
is the notion that areas distal from the site of injury are affected, should not be ignored, and 
further investigated.  
 
5.2 Limitations 
The limitations of each of the studies presented in this thesis have been discussed in detail in their 
respective chapters. However, a general limitation of searching for predictors of surgical outcome 
for the CSM population is the classification into severity subgroups. CSM patients are highly 
heterogeneous with symptoms ranging from mild to severe and affecting both upper and lower 
limbs. Stricter categorization determinants are required in identifying the difference between the 
CSM subgroups: mild, moderate and severe. Currently, the categorization of CSM to a severity 
subgroup is strictly based on the mJOA score. However, the mJOA score is a subjective 
questionnaire completed by the patient and does not take into account the findings from the 
neurological exam or the imaging results. A classification system should consider all findings 
during a clinic visit, specifically: the new updated JOAMCEQ-L questionnaire, neurological 
signs and symptoms, and findings on MR imaging. 
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This thesis introduced great insight into the cortical changes of the CSM patient population that 
can be measured non-invasively using MR techniques. Specifically, changes in the NAA 
concentrations were found in the primary motor cortex CSM patients suggesting neuronal death 
and/or mitochondrial dysfunction. The differences in the NAA concentration were between the 
mild and moderate CSM group at the pre-operative time point. The NAA concentrations could be 
used as predictors of outcome or biomarkers reflecting an underlying structural or physiological 
event. However, this cannot be confirmed until the affected neurons (with decreased NAA) are 
directly evaluated in the cortex. This is not possible as it would involve an invasive operation and 
damaging the white matter itself. Instead, animal models of CSM may prove to be useful in 
understanding the basic mechanisms of neuronal death or dysfunction in the motor cortex in 
hopes of devising a marker that can predict conservative and surgical outcome. 
 
5.3 Future Directions 
This thesis introduced important findings regarding the cortical changes of the CSM patient 
population that can be measured using novel non-invasive MRI techniques. It is important to 
address the injury occurring at the level of the spinal cord, and downstream in the cortex. The 
measured cortical changes, specifically NAA and VOAs, were able to discriminate between the 
mild and moderate CSM groups. However, in order to create a predictor of outcome in the CSM 
patient population, we must first look at the mild CSM population who do not receive surgical 
intervention. Research has shown that some patients are able to benefit from conservative 
treatment and do not need to undergo surgical intervention. Measuring the longitudinal 
metabolite and functional changes in the mild CSM group who do not undergo decompressive 
surgery builds on the early work of this thesis in an effort to understand the natural history of 
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CSM. Following an exploration into the natural progression of CSM, accurate predictors and 
biomarkers can be evaluated in aiding the evaluation and management of the patient population.  
 
Secondly, the metabolite concentrations were only measured in the primary motor cortex 
contralateral to the greater deficit side in the CSM population. It would be valuable to investigate 
the metabolite alterations in mild CSM patients treated conservatively, and mild and moderate 
CSM patients treated surgically, bilaterally in the primary motor cortex. This would provide a 
further understanding of the pathophysiology of CSM and the adaptations the cortex makes to 
accommodate for the loss in function. It would be interesting to determine whether the same 
changes occur bilaterally, or if the greater deficit side experiences more injury. Following these 
three groups longitudinally would provide insight into the possible role of brain plasticity in the 
preservation or recovery of neurological function. The metabolite concentrations should also be 
correlated to functional changes measured by fMRI during a finger tapping task and clinical 
status measured by the new updated JOACMEQ-L.  
 
5.4 Conclusions 
Each of these studies offered new information on cortical adaptations in the primary motor cortex 
and identified possible biomarkers to better understand and classify CSM based on injury 
severity. The most pertinent findings presented in this thesis are as follows: 1) The primary motor 
cortex undergoes cortical reorganization in CSM patients; 2) NAA/Cr is decreased in CSM 
patients prior to and following surgical intervention despite neurological recovery; 3) Mild and 
moderate CSM patients present different metabolic concentrations and functional activations; and 
4) Following surgery, both groups experience neurological improvement and show an activation 
135 
centered on the primary sensory cortex and same low levels of NAA/Cr. Each of these studies 
presented a new approach at identifying and classifying the severity of CSM. These novel non-
invasive imaging assessments are able to provide adjunctive information and hopefully will 
provide a more precise understanding of the functional and metabolic pathways that may 
ultimately be incorporated into clinical decision making. The goal is to gain further 
understanding of the pathophysiology of CSM and evaluate new diagnostic tools. These sensitive 
imaging biomarkers may foreshadow clinical deterioration and provide predictive information to 
further tailor the treatment of CSM on a patient-by-patient basis. 
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